These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
| (State or other jurisdiction | (IRS employer | |||||||
| of incorporation or organization) | identification number) | |||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
|
|
|
|
||||||||||||
|
|
|
|
||||||||||||
|
|
|
|
||||||||||||
| Item | Page | |||||||||||||
| PART I – FINANCIAL INFORMATION | ||||||||||||||
| 1 | Financial Statements (Unaudited) as of March 31, 2023 and December 31, 2022 and for the Three Months Ended March 31, 2023 and 2022 | |||||||||||||
| Notes to Condensed Consolidated Financial Statements (Unaudited) | ||||||||||||||
| 2 | ||||||||||||||
| 3 | ||||||||||||||
| 4 | ||||||||||||||
| PART II – OTHER INFORMATION | ||||||||||||||
| 1 | ||||||||||||||
| 1A | ||||||||||||||
| 2 | ||||||||||||||
| 6 | ||||||||||||||
|
March 31,
2023 |
December 31,
2022 |
|||||||||||||
|
Assets
|
||||||||||||||
|
Fixed maturity securities available-for-sale, at fair value (amortized cost of $
|
$ |
|
$ |
|
||||||||||
| Equity securities, at fair value |
|
|
||||||||||||
|
Mortgage loans (net of allowance for credit losses of $
|
|
|
||||||||||||
| Policy loans |
|
|
||||||||||||
| Funds withheld at interest |
|
|
||||||||||||
| Limited partnerships and real estate joint ventures |
|
|
||||||||||||
| Short-term investments |
|
|
||||||||||||
| Other invested assets |
|
|
||||||||||||
| Total investments |
|
|
||||||||||||
| Cash and cash equivalents |
|
|
||||||||||||
| Accrued investment income |
|
|
||||||||||||
| Premiums receivable and other reinsurance balances |
|
|
||||||||||||
| Reinsurance ceded receivables and other |
|
|
||||||||||||
| Deferred policy acquisition costs |
|
|
||||||||||||
| Other assets |
|
|
||||||||||||
| Total assets | $ |
|
$ |
|
||||||||||
| Liabilities and equity | ||||||||||||||
| Future policy benefits | $ |
|
$ |
|
||||||||||
| Interest-sensitive contract liabilities |
|
|
||||||||||||
| Market risk benefits, at fair value |
|
|
||||||||||||
| Other policy claims and benefits |
|
|
||||||||||||
| Other reinsurance balances |
|
|
||||||||||||
| Deferred income taxes |
|
|
||||||||||||
| Other liabilities |
|
|
||||||||||||
| Long-term debt |
|
|
||||||||||||
| Total liabilities |
|
|
||||||||||||
| Commitments and contingent liabilities (See Note 16) |
|
|
||||||||||||
| Equity | ||||||||||||||
|
Preferred stock – par value $
|
|
|
||||||||||||
|
Common stock – par value $
|
|
|
||||||||||||
| Additional paid-in-capital |
|
|
||||||||||||
| Retained earnings |
|
|
||||||||||||
|
Treasury stock, at cost –
|
(
|
(
|
||||||||||||
| Accumulated other comprehensive income (loss) |
(
|
(
|
||||||||||||
| Total RGA, Inc. stockholders’ equity |
|
|
||||||||||||
| Noncontrolling interest |
|
|
||||||||||||
| Total equity |
|
|
||||||||||||
| Total liabilities and stockholders’ equity | $ |
|
$ |
|
||||||||||
| Three months ended March 31, | ||||||||||||||||||||||||||
| 2023 | 2022 | |||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||||
| Net premiums | $ |
|
$ |
|
||||||||||||||||||||||
| Net investment income |
|
|
||||||||||||||||||||||||
| Investment related gains (losses), net |
(
|
(
|
||||||||||||||||||||||||
| Other revenues |
|
|
||||||||||||||||||||||||
| Total revenues |
|
|
||||||||||||||||||||||||
| Benefits and expenses | ||||||||||||||||||||||||||
| Claims and other policy benefits |
|
|
||||||||||||||||||||||||
| Future policy benefits remeasurement (gains) losses |
(
|
|
||||||||||||||||||||||||
| Market risk benefits remeasurement (gains) losses |
|
(
|
||||||||||||||||||||||||
| Interest credited |
|
|
||||||||||||||||||||||||
| Policy acquisition costs and other insurance expenses |
|
|
||||||||||||||||||||||||
| Other operating expenses |
|
|
||||||||||||||||||||||||
| Interest expense |
|
|
||||||||||||||||||||||||
| Collateral finance and securitization expense |
|
|
||||||||||||||||||||||||
| Total benefits and expenses |
|
|
||||||||||||||||||||||||
|
Income before income taxes
|
|
|
||||||||||||||||||||||||
| Provision for income taxes |
|
|
||||||||||||||||||||||||
| Net income |
|
|
||||||||||||||||||||||||
| Net income attributable to noncontrolling interest |
|
|
||||||||||||||||||||||||
| Net income available to RGA, Inc. shareholders | $ |
|
$ |
|
||||||||||||||||||||||
| Earnings per share | ||||||||||||||||||||||||||
| Basic earnings per share | $ |
|
$ |
|
||||||||||||||||||||||
| Diluted earnings per share | $ |
|
$ |
|
||||||||||||||||||||||
| Three months ended March 31, | ||||||||||||||||||||||||||
| 2023 | 2022 | |||||||||||||||||||||||||
| Comprehensive income (loss) | ||||||||||||||||||||||||||
| Net income | $ |
|
$ |
|
||||||||||||||||||||||
| Other comprehensive income (loss), net of tax: | ||||||||||||||||||||||||||
| Foreign currency translation adjustments |
|
|
||||||||||||||||||||||||
| Net unrealized investment gains (losses) |
|
(
|
||||||||||||||||||||||||
| Effect of updating discount rates on future policy benefits |
(
|
|
||||||||||||||||||||||||
| Change in instrument-specific credit risk for market risk benefits |
|
(
|
||||||||||||||||||||||||
| Defined benefit pension and postretirement plan adjustments |
|
|
||||||||||||||||||||||||
| Total other comprehensive income (loss), net of tax |
|
(
|
||||||||||||||||||||||||
| Total comprehensive income (loss) |
|
(
|
||||||||||||||||||||||||
| Comprehensive income attributable to noncontrolling interest |
|
|
||||||||||||||||||||||||
| Total comprehensive income (loss) attributable to RGA, Inc. | $ |
|
$ |
(
|
||||||||||||||||||||||
| RGA, Inc. Stockholders’ Equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Common
Stock |
Additional Paid In Capital |
Retained
Earnings |
Treasury
Stock |
Accumulated Other Comprehensive Income (Loss) | Total RGA, Inc. Stockholders’ Equity | Noncontrolling Interest | Total Equity | ||||||||||||||||||||||||||||||||||||||||||||||
| Balance, December 31, 2022 | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||||||||
| Change in equity of noncontrolling interest |
(
|
(
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
| Total other comprehensive income (loss) |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Dividends to stockholders, $
|
(
|
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchase of treasury stock |
(
|
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Reissuance of treasury stock |
|
(
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2023 | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||||||||||||
| RGA, Inc. Stockholders’ Equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Common
Stock |
Additional Paid In Capital |
Retained
Earnings |
Treasury
Stock |
Accumulated Other Comprehensive Income (Loss) | Total RGA, Inc. Stockholders’ Equity | Noncontrolling Interest | Total Equity | ||||||||||||||||||||||||||||||||||||||||||||||
| Balance, December 31, 2021 | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||||||||
| Issuance of preferred interests by subsidiary |
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Total other comprehensive income (loss) |
(
|
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||||||||||
|
Dividends to stockholders, $
|
(
|
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchase of treasury stock |
(
|
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Reissuance of treasury stock |
|
(
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2022 | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||||||||||||
| Three months ended March 31, | ||||||||||||||
| 2023 | 2022 | |||||||||||||
| Net cash provided by operating activities |
|
|
||||||||||||
| Cash flows from investing activities | ||||||||||||||
| Sales of fixed maturity securities available-for-sale |
|
|
||||||||||||
| Purchases of fixed maturity securities available-for-sale |
(
|
(
|
||||||||||||
| Maturities of fixed maturity securities available-for-sale |
|
|
||||||||||||
| Sales of equity securities |
|
|
||||||||||||
| Purchases of equity securities |
(
|
|
||||||||||||
| Principal payments on mortgage loans |
|
|
||||||||||||
| Cash invested in mortgage loans |
(
|
(
|
||||||||||||
| Net change in policy loans |
|
|
||||||||||||
| Cash invested in funds withheld at interest, net |
|
(
|
||||||||||||
| Sales of limited partnerships and real estate joint ventures |
|
|
||||||||||||
| Purchases of limited partnerships and real estate joint ventures |
(
|
(
|
||||||||||||
| Change in short-term investments |
(
|
(
|
||||||||||||
| Change in other invested assets |
|
(
|
||||||||||||
| Purchases of property and equipment |
(
|
(
|
||||||||||||
| Net cash used in investing activities |
(
|
(
|
||||||||||||
| Cash flows from financing activities | ||||||||||||||
| Dividends to stockholders |
(
|
(
|
||||||||||||
| Repayment of collateral finance and securitization notes |
|
(
|
||||||||||||
| Proceeds from long-term debt issuance |
|
|
||||||||||||
| Debt issuance costs |
(
|
|
||||||||||||
| Principal payments of long-term debt |
(
|
(
|
||||||||||||
| Purchases of treasury stock |
(
|
(
|
||||||||||||
| Change in cash collateral for derivative positions and other arrangements |
|
(
|
||||||||||||
| Change in deposit asset on reinsurance |
|
(
|
||||||||||||
| Deposits on investment-type policies and contracts |
|
|
||||||||||||
| Withdrawals on investment-type policies and contracts |
(
|
(
|
||||||||||||
| Net change in noncontrolling interest |
|
|
||||||||||||
| Net cash provided by financing activities |
|
|
||||||||||||
| Effect of exchange rate changes on cash |
|
(
|
||||||||||||
| Change in cash and cash equivalents |
|
(
|
||||||||||||
| Cash and cash equivalents, beginning of period |
|
|
||||||||||||
| Cash and cash equivalents, end of period | $ |
|
$ |
|
||||||||||
| Supplemental disclosures of cash flow information | ||||||||||||||
| Interest paid | $ |
|
$ |
|
||||||||||
| Income taxes paid, net of refunds | $ |
|
$ |
|
||||||||||
| Non-cash investing activities | ||||||||||||||
| Transfer of invested assets | $ |
|
$ |
|
||||||||||
| January 1, 2021 | ||||||||||||||
| Retained Earnings | Accumulated Other Comprehensive Income (Loss) | |||||||||||||
| Reinsurance ceded receivables and other | $ |
|
$ |
|
||||||||||
| Future policy benefits |
(
|
(
|
||||||||||||
| Market risk benefits |
(
|
|
||||||||||||
| Deferred policy acquisition costs |
|
|
||||||||||||
| Deferred tax asset (included in other assets) |
|
|
||||||||||||
| Deferred tax liability (included in deferred income taxes) |
|
|
||||||||||||
| Total | $ |
(
|
$ |
(
|
||||||||||
| U.S. and Latin America – Traditional | Canada – Traditional | Europe, Middle East and Africa – Traditional | Asia Pacific – Traditional | |||||||||||||||||||||||
| Future policy benefits | ||||||||||||||||||||||||||
| Balance, January 1, 2021 pre-adoption | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
Adjustment to retained earnings
(1)
|
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
|
|
|
(
|
||||||||||||||||||||||
|
Reclassification of claims and benefits payable
(2)
|
|
|
|
|
||||||||||||||||||||||
| Balance, January 1, 2021 post-adoption | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Less: reinsurance recoverable |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Balance, January 1, 2021 post-adoption, after reinsurance | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| U.S. and Latin America – Financial Solutions | Canada – Financial Solutions | Europe, Middle East and Africa – Financial Solutions | Asia Pacific – Financial Solutions | |||||||||||||||||||||||
| Future policy benefits | ||||||||||||||||||||||||||
| Balance, January 1, 2021 pre-adoption | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
Adjustment to retained earnings
(1)
|
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
|
|
|
|
||||||||||||||||||||||
|
Amounts previously recorded in AOCI
(2)
|
(
|
|
|
|
||||||||||||||||||||||
|
Reclassification of claims and benefits payable
(3)
|
|
|
|
|
||||||||||||||||||||||
| Balance, January 1, 2021 post-adoption | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Less: reinsurance recoverable |
|
|
|
|
||||||||||||||||||||||
| Balance, January 1, 2021 post-adoption, after reinsurance | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Market risk benefits | ||||||||||||||||||||||||||
| Balance, January 1, 2021 pre-adoption | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Cumulative effect of change in credit risk in AOCI |
(
|
|
|
|
||||||||||||||||||||||
| Cumulative effect to retained earnings |
|
|
|
|
||||||||||||||||||||||
| Reclassification from interest-sensitive contract liabilities |
|
|
|
|
||||||||||||||||||||||
| Balance, January 1, 2021 post-adoption | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Less: reinsurance recoverable |
|
|
|
|
||||||||||||||||||||||
| Balance, January 1, 2021 post-adoption, after reinsurance | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Deferred policy acquisition costs | ||||||||||||||||||||||||||
| Balance, January 1, 2021 pre-adoption | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
Amounts previously recorded in AOCI
(2)
|
|
|
|
|
||||||||||||||||||||||
| Balance, January 1, 2021 post-adoption | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| As Previously Reported | Adoption of ASU 2018-12 | As Adjusted | ||||||||||||||||||
| Consolidated Balance Sheets | ||||||||||||||||||||
| December 31, 2022 | ||||||||||||||||||||
| Assets | ||||||||||||||||||||
| Fixed maturity securities available-for-sale, at fair value | $ |
|
$ |
|
$ |
|
||||||||||||||
| Equity securities, at fair value |
|
|
|
|||||||||||||||||
| Mortgage loans |
|
|
|
|||||||||||||||||
| Policy loans |
|
|
|
|||||||||||||||||
| Funds withheld at interest |
|
|
|
|||||||||||||||||
| Limited partnerships and real estate joint ventures |
|
|
|
|||||||||||||||||
| Short-term investments |
|
|
|
|||||||||||||||||
| Other invested assets |
|
|
|
|||||||||||||||||
| Total investments |
|
|
|
|||||||||||||||||
| Cash and cash equivalents |
|
|
|
|||||||||||||||||
| Accrued investment income |
|
|
|
|||||||||||||||||
| Premiums receivable and other reinsurance balances |
|
|
|
|||||||||||||||||
| Reinsurance ceded receivables and other |
|
|
|
|||||||||||||||||
| Deferred policy acquisition costs |
|
|
|
|||||||||||||||||
| Other assets |
|
(
|
|
|||||||||||||||||
| Total assets | $ |
|
$ |
|
$ |
|
||||||||||||||
| Liabilities and equity | ||||||||||||||||||||
| Future policy benefits |
|
|
|
|||||||||||||||||
| Interest-sensitive contract liabilities |
|
(
|
|
|||||||||||||||||
| Market risk benefits, at fair value |
|
|
|
|||||||||||||||||
| Other policy claims and benefits |
|
(
|
|
|||||||||||||||||
| Other reinsurance balances |
|
(
|
|
|||||||||||||||||
| Deferred income taxes |
|
|
|
|||||||||||||||||
| Other liabilities |
|
|
|
|||||||||||||||||
| Long-term debt |
|
|
|
|||||||||||||||||
| Total liabilities |
|
(
|
|
|||||||||||||||||
| Equity | ||||||||||||||||||||
| Preferred stock |
|
|
|
|||||||||||||||||
| Common stock |
|
|
|
|||||||||||||||||
| Additional paid-in-capital |
|
|
|
|||||||||||||||||
| Retained earnings |
|
(
|
|
|||||||||||||||||
| Treasury stock, at cost |
(
|
|
(
|
|||||||||||||||||
| Accumulated other comprehensive income (loss) |
(
|
|
(
|
|||||||||||||||||
| Total RGA, Inc. stockholders’ equity |
|
|
|
|||||||||||||||||
| Noncontrolling interest |
|
|
|
|||||||||||||||||
| Total equity |
|
|
|
|||||||||||||||||
| Total liabilities and stockholders’ equity | $ |
|
$ |
|
$ |
|
||||||||||||||
| As Previously Reported | Adoption of ASU 2018-12 | As Adjusted | ||||||||||||||||||
| December 31, 2021 | ||||||||||||||||||||
| Assets | ||||||||||||||||||||
| Fixed maturity securities available-for-sale, at fair value | $ |
|
$ |
|
$ |
|
||||||||||||||
| Equity securities, at fair value |
|
|
|
|||||||||||||||||
| Mortgage loans |
|
|
|
|||||||||||||||||
| Policy loans |
|
|
|
|||||||||||||||||
| Funds withheld at interest |
|
|
|
|||||||||||||||||
| Limited partnerships and real estate joint ventures |
|
|
|
|||||||||||||||||
| Short-term investments |
|
|
|
|||||||||||||||||
| Other invested assets |
|
|
|
|||||||||||||||||
| Total investments |
|
|
|
|||||||||||||||||
| Cash and cash equivalents |
|
|
|
|||||||||||||||||
| Accrued investment income |
|
|
|
|||||||||||||||||
| Premiums receivable and other reinsurance balances |
|
|
|
|||||||||||||||||
| Reinsurance ceded receivables and other |
|
|
|
|||||||||||||||||
| Deferred policy acquisition costs |
|
|
|
|||||||||||||||||
| Other assets |
|
|
|
|||||||||||||||||
| Total assets | $ |
|
$ |
|
$ |
|
||||||||||||||
| Liabilities and equity | ||||||||||||||||||||
| Future policy benefits |
|
|
|
|||||||||||||||||
| Interest-sensitive contract liabilities |
|
(
|
|
|||||||||||||||||
| Market risk benefits, at fair value |
|
|
|
|||||||||||||||||
| Other policy claims and benefits |
|
(
|
|
|||||||||||||||||
| Other reinsurance balances |
|
(
|
|
|||||||||||||||||
| Deferred income taxes |
|
(
|
|
|||||||||||||||||
| Other liabilities |
|
|
|
|||||||||||||||||
| Long-term debt |
|
|
|
|||||||||||||||||
| Collateral finance and securitization notes |
|
|
|
|||||||||||||||||
| Total liabilities |
|
|
|
|||||||||||||||||
| Equity | ||||||||||||||||||||
| Preferred stock |
|
|
|
|||||||||||||||||
| Common stock |
|
|
|
|||||||||||||||||
| Additional paid-in-capital |
|
|
|
|||||||||||||||||
| Retained earnings |
|
(
|
|
|||||||||||||||||
| Treasury stock, at cost |
(
|
|
(
|
|||||||||||||||||
| Accumulated other comprehensive income (loss) |
|
(
|
(
|
|||||||||||||||||
| Total RGA, Inc. stockholders’ equity |
|
(
|
|
|||||||||||||||||
| Noncontrolling interest |
|
|
|
|||||||||||||||||
| Total equity |
|
(
|
|
|||||||||||||||||
| Total liabilities and stockholders’ equity | $ |
|
$ |
|
$ |
|
||||||||||||||
| As Previously Reported | Adoption of ASU 2018-12 | As Adjusted | ||||||||||||||||||
| Consolidated Statements of Income | ||||||||||||||||||||
| Year ended December 31, 2022 | ||||||||||||||||||||
| Revenues | ||||||||||||||||||||
| Net premiums | $ |
|
$ |
|
$ |
|
||||||||||||||
| Net investment income |
|
|
|
|||||||||||||||||
| Investment related gains (losses), net |
(
|
(
|
(
|
|||||||||||||||||
| Other revenues |
|
|
|
|||||||||||||||||
| Total revenues |
|
(
|
|
|||||||||||||||||
| Benefits and expenses | ||||||||||||||||||||
| Claims and other policy benefits |
|
(
|
|
|||||||||||||||||
| Future policy benefits remeasurement (gains) losses |
|
|
|
|||||||||||||||||
| Market risk benefits remeasurement (gains) losses |
|
|
|
|||||||||||||||||
| Interest credited |
|
|
|
|||||||||||||||||
| Policy acquisition costs and other insurance expenses |
|
(
|
|
|||||||||||||||||
| Other operating expenses |
|
|
|
|||||||||||||||||
| Interest expense |
|
|
|
|||||||||||||||||
| Collateral finance and securitization expense |
|
|
|
|||||||||||||||||
| Total benefits and expenses |
|
|
|
|||||||||||||||||
| Income before income taxes |
|
(
|
|
|||||||||||||||||
| Provision for income taxes |
|
(
|
|
|||||||||||||||||
| Net income | $ |
|
$ |
(
|
$ |
|
||||||||||||||
| Net income attributable to noncontrolling interest |
|
|
|
|||||||||||||||||
| Net income available to RGA, Inc. shareholders | $ |
|
$ |
(
|
$ |
|
||||||||||||||
| As Previously Reported | Adoption of ASU 2018-12 | As Adjusted | ||||||||||||||||||
| Year ended December 31, 2021 | ||||||||||||||||||||
| Revenues | ||||||||||||||||||||
| Net premiums | $ |
|
$ |
|
$ |
|
||||||||||||||
| Net investment income |
|
|
|
|||||||||||||||||
| Investment related gains (losses), net |
|
|
|
|||||||||||||||||
| Other revenues |
|
|
|
|||||||||||||||||
| Total revenues |
|
|
|
|||||||||||||||||
| Benefits and expenses | ||||||||||||||||||||
| Claims and other policy benefits |
|
(
|
|
|||||||||||||||||
| Future policy benefits remeasurement (gains) losses |
|
|
|
|||||||||||||||||
| Market risk benefits remeasurement (gains) losses |
|
(
|
(
|
|||||||||||||||||
| Interest credited |
|
|
|
|||||||||||||||||
| Policy acquisition costs and other insurance expenses |
|
(
|
|
|||||||||||||||||
| Other operating expenses |
|
|
|
|||||||||||||||||
| Interest expense |
|
|
|
|||||||||||||||||
| Collateral finance and securitization expense |
|
|
|
|||||||||||||||||
| Total benefits and expenses |
|
(
|
|
|||||||||||||||||
| Income before income taxes |
|
|
|
|||||||||||||||||
| Provision for income taxes |
|
|
|
|||||||||||||||||
| Net income | $ |
|
$ |
|
$ |
|
||||||||||||||
| Net income attributable to noncontrolling interest |
|
|
|
|||||||||||||||||
| Net income available to RGA, Inc. shareholders | $ |
|
$ |
|
$ |
|
||||||||||||||
| As Previously Reported | Adoption of ASU 2018-12 | As Adjusted | ||||||||||||||||||
| Consolidated Statements of Comprehensive Income | ||||||||||||||||||||
| Year ended December 31, 2022 | ||||||||||||||||||||
| Net income | $ |
|
$ |
(
|
$ |
|
||||||||||||||
| Other comprehensive income (loss), net of tax | ||||||||||||||||||||
| Foreign currency translation adjustments |
(
|
|
(
|
|||||||||||||||||
| Net unrealized investment gains (losses) |
(
|
(
|
(
|
|||||||||||||||||
| Effect of updating discount rates on future policy benefits |
|
|
|
|||||||||||||||||
| Change in instrument-specific credit risk for market risk benefits |
|
|
|
|||||||||||||||||
| Defined benefit pension and postretirement plan adjustments |
|
|
|
|||||||||||||||||
| Total other comprehensive income (loss), net of tax |
(
|
|
(
|
|||||||||||||||||
| Total comprehensive income (loss) |
(
|
|
(
|
|||||||||||||||||
| Comprehensive income (loss) attributable to noncontrolling interest |
|
|
|
|||||||||||||||||
| Total comprehensive income (loss) available to RGA, Inc. | $ |
(
|
$ |
|
$ |
(
|
||||||||||||||
| Year ended December 31, 2021 | ||||||||||||||||||||
| Net income | $ |
|
$ |
|
$ |
|
||||||||||||||
| Other comprehensive income (loss), net of tax | ||||||||||||||||||||
| Foreign currency translation adjustments |
|
(
|
|
|||||||||||||||||
| Net unrealized investment gains (losses) |
(
|
(
|
(
|
|||||||||||||||||
| Effect of updating discount rates on future policy benefits |
|
|
|
|||||||||||||||||
| Change in instrument-specific credit risk for market risk benefits |
|
(
|
(
|
|||||||||||||||||
| Defined benefit pension and postretirement plan adjustments |
|
|
|
|||||||||||||||||
| Total other comprehensive income (loss), net of tax |
(
|
|
|
|||||||||||||||||
| Total comprehensive income (loss) |
(
|
|
|
|||||||||||||||||
| Comprehensive income (loss) attributable to noncontrolling interest |
|
|
|
|||||||||||||||||
| Total comprehensive income (loss) available to RGA, Inc. | $ |
(
|
$ |
|
$ |
|
||||||||||||||
| RGA, Inc. Stockholders’ Equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Common
Stock |
Additional Paid In Capital |
Retained
Earnings |
Treasury
Stock |
Accumulated Other Comprehensive Income (Loss) | Total RGA, Inc. Stockholders’ Equity | Noncontrolling Interest | Total Equity | ||||||||||||||||||||||||||||||||||||||||||||||
| Balance, December 31, 2020 as previously reported | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||||||||||||
|
Cumulative effect of modified retrospective adoption of
Financial Services – Insurance
on long-duration contracts
|
(
|
(
|
(
|
(
|
|||||||||||||||||||||||||||||||||||||||||||||||||
|
Cumulative effect of full retrospective adoption of
Financial Services – Insurance
on market risk benefits
|
(
|
|
(
|
(
|
|||||||||||||||||||||||||||||||||||||||||||||||||
| Adjusted balance, January 1, 2021 |
|
|
|
(
|
(
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Net income |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Total other comprehensive income (loss) |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Dividends to stockholders, $2.86 per share |
(
|
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchase of treasury stock |
(
|
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Reissuance of treasury stock |
|
(
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, December, 31, 2021 |
|
|
|
(
|
(
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Issuance of preferred interests by subsidiary |
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Change in equity of noncontrolling interest |
(
|
(
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Net income |
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||
| Total other comprehensive income (loss) |
(
|
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Dividends to stockholders, $3.06 per share |
(
|
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Purchase of treasury stock |
(
|
(
|
(
|
||||||||||||||||||||||||||||||||||||||||||||||||||
| Reissuance of treasury stock |
|
(
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, December 31, 2022 | $ |
|
$ |
|
$ |
|
$ |
(
|
$ |
(
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||||||||||||
|
For the year ended December 31, 2022:
|
U.S. and Latin America – Traditional | Canada – Traditional | Europe, Middle East and Africa – Traditional | Asia Pacific – Traditional | ||||||||||||||||||||||
| Present Value of Expected Net Premiums | ||||||||||||||||||||||||||
| Beginning of year balance at original discount rate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Effect of changes in cash flow assumptions |
(
|
|
|
|
||||||||||||||||||||||
| Effect of actual variances from expected experience |
(
|
|
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
|
Issuances
(1)
|
|
|
|
|
||||||||||||||||||||||
|
Interest accrual
(2)
|
|
|
|
|
||||||||||||||||||||||
|
Net premiums collected
(3)
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||
|
Derecognition
(4)
|
|
|
|
|
||||||||||||||||||||||
| Foreign currency translation |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Ending balance at original discount rate |
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Present Value of Expected Future Policy Benefits | ||||||||||||||||||||||||||
| Beginning of year balance at original discount rate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Effect of changes in cash flow assumptions |
(
|
|
|
|
||||||||||||||||||||||
| Effect of actual variances from expected experience |
|
|
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
|
Issuances
(1)
|
|
|
|
|
||||||||||||||||||||||
|
Interest accrual
(2)
|
|
|
|
|
||||||||||||||||||||||
|
Benefit payments
(5)
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||
|
Derecognition
(4)
|
|
|
|
|
||||||||||||||||||||||
| Foreign currency translation |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Ending balance at original discount rate |
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Liability for future policy benefits | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Less: reinsurance recoverable |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Net liability for future policy benefits | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
For the year ended December 31, 2021:
|
U.S. and Latin America – Traditional | Canada – Traditional | Europe, Middle East and Africa – Traditional | Asia Pacific – Traditional | ||||||||||||||||||||||
| Present Value of Expected Net Premiums | ||||||||||||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
Effect of adoption of
Financial Services
–
Insurance
|
|
|
|
(
|
||||||||||||||||||||||
| Adjusted balance, beginning of year | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Beginning of year balance at original discount rate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Effect of changes in cash flow assumptions |
|
(
|
|
|
||||||||||||||||||||||
| Effect of actual variances from expected experience |
|
(
|
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
|
Issuances
(1)
|
|
|
|
|
||||||||||||||||||||||
|
Interest accrual
(2)
|
|
|
|
|
||||||||||||||||||||||
|
Net premiums collected
(3)
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||
|
Derecognition
(4)
|
|
|
(
|
|
||||||||||||||||||||||
| Foreign currency translation |
(
|
|
(
|
(
|
||||||||||||||||||||||
| Ending balance at original discount rate |
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
|
(
|
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Present Value of Expected Future Policy Benefits | ||||||||||||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
Effect of adoption of
Financial Services
–
Insurance
|
|
|
|
(
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
| Beginning of year balance at original discount rate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Effect of changes in cash flow assumptions |
|
(
|
|
|
||||||||||||||||||||||
| Effect of actual variances from expected experience |
|
(
|
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
|
Issuances
(1)
|
|
|
|
|
||||||||||||||||||||||
|
Interest accrual
(2)
|
|
|
|
|
||||||||||||||||||||||
|
Benefit payments
(5)
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||
|
Derecognition
(4)
|
|
|
(
|
|
||||||||||||||||||||||
| Foreign currency translation |
(
|
|
(
|
(
|
||||||||||||||||||||||
| Ending balance at original discount rate |
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
|
|
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Liability for future policy benefits | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Less: reinsurance recoverable |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Net liability for future policy benefits | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
For the year ended December 31, 2022:
|
U.S. and Latin America – Financial Solutions | Canada – Financial Solutions | Europe, Middle East and Africa – Financial Solutions | Asia Pacific – Financial Solutions | ||||||||||||||||||||||
| Present Value of Expected Net Premiums | ||||||||||||||||||||||||||
| Beginning of year balance at original discount rate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Effect of changes in cash flow assumptions |
(
|
|
(
|
|
||||||||||||||||||||||
| Effect of actual variances from expected experience |
(
|
(
|
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
|
Issuances
(1)
|
|
|
|
|
||||||||||||||||||||||
|
Interest accrual
(2)
|
|
|
|
|
||||||||||||||||||||||
|
Net premiums collected
(3)
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||
|
Derecognition
(4)
|
|
|
|
|
||||||||||||||||||||||
| Foreign currency translation |
|
(
|
(
|
(
|
||||||||||||||||||||||
| Ending balance at original discount rate |
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
(
|
(
|
(
|
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Present Value of Expected Future Policy Benefits | ||||||||||||||||||||||||||
| Beginning of year balance at original discount rate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Effect of changes in cash flow assumptions |
(
|
|
(
|
|
||||||||||||||||||||||
| Effect of actual variances from expected experience |
(
|
(
|
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
|
Issuances
(1)
|
|
|
|
|
||||||||||||||||||||||
|
Interest accrual
(2)
|
|
|
|
|
||||||||||||||||||||||
|
Benefit payments
(5)
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||
|
Derecognition
(4)
|
|
|
|
|
||||||||||||||||||||||
| Foreign currency translation |
|
(
|
(
|
(
|
||||||||||||||||||||||
| Ending balance at original discount rate |
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Liability for future policy benefits | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Less: reinsurance recoverable |
|
|
|
|
||||||||||||||||||||||
| Net liability for future policy benefits | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
For the year ended December 31, 2021:
|
U.S. and Latin America – Financial Solutions | Canada – Financial Solutions | Europe, Middle East and Africa – Financial Solutions | Asia Pacific – Financial Solutions | ||||||||||||||||||||||
| Present Value of Expected Net Premiums | ||||||||||||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
Effect of adoption of
Financial Services
–
Insurance
|
|
|
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
| Beginning of year balance at original discount rate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Effect of changes in cash flow assumptions |
(
|
(
|
(
|
|
||||||||||||||||||||||
| Effect of actual variances from expected experience |
(
|
|
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
|
Issuances
(1)
|
|
|
|
|
||||||||||||||||||||||
|
Interest accrual
(2)
|
|
|
|
|
||||||||||||||||||||||
|
Net premiums collected
(3)
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||
|
Derecognition
(4)
|
|
|
(
|
|
||||||||||||||||||||||
| Foreign currency translation |
|
|
(
|
(
|
||||||||||||||||||||||
| Ending balance at original discount rate |
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
|
|
|
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Present Value of Expected Future Policy Benefits | ||||||||||||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
Effect of adoption of
Financial Services
–
Insurance
|
|
|
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
| Beginning of year balance at original discount rate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Effect of changes in cash flow assumptions |
(
|
|
(
|
|
||||||||||||||||||||||
| Effect of actual variances from expected experience |
(
|
|
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
|
Issuances
(1)
|
|
|
|
|
||||||||||||||||||||||
|
Interest accrual
(2)
|
|
|
|
|
||||||||||||||||||||||
|
Benefit payments
(5)
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||
|
Derecognition
(4)
|
|
|
(
|
|
||||||||||||||||||||||
| Foreign currency translation |
|
|
(
|
(
|
||||||||||||||||||||||
| Ending balance at original discount rate |
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
|
|
|
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Liability for future policy benefits | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Less: reinsurance recoverable |
|
|
|
|
||||||||||||||||||||||
| Net liability for future policy benefits | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
For the year ended December 31, 2022:
|
U.S. and Latin America – Traditional | U.S. and Latin America – Financial Solutions | Asia Pacific – Financial Solutions | |||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
||||||||||||||
| Deposits |
|
|
|
|||||||||||||||||
| Policy charges |
(
|
(
|
(
|
|||||||||||||||||
| Surrenders and withdrawals |
(
|
(
|
(
|
|||||||||||||||||
| Benefit payments |
(
|
(
|
(
|
|||||||||||||||||
| Interest credited |
|
|
|
|||||||||||||||||
| Foreign currency translation |
|
|
(
|
|||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
||||||||||||||
| Less: reinsurance recoverable |
|
(
|
|
|||||||||||||||||
| Balance, end of period, after reinsurance | $ |
|
$ |
|
$ |
|
||||||||||||||
|
For the year ended December 31, 2021:
|
U.S. and Latin America – Traditional | U.S. and Latin America – Financial Solutions | Asia Pacific – Financial Solutions | |||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
||||||||||||||
| Deposits |
|
|
|
|||||||||||||||||
| Policy charges |
(
|
(
|
(
|
|||||||||||||||||
| Surrenders and withdrawals |
(
|
(
|
(
|
|||||||||||||||||
| Benefit payments |
(
|
(
|
(
|
|||||||||||||||||
| Interest credited |
|
|
|
|||||||||||||||||
| Foreign currency translation |
|
|
(
|
|||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
||||||||||||||
| Less: reinsurance recoverable |
|
(
|
|
|||||||||||||||||
| Balance, end of period, after reinsurance | $ |
|
$ |
|
$ |
|
||||||||||||||
|
For the year ended December 31, 2022:
|
U.S. and Latin America – Financial Solutions | |||||||
| Balance, beginning of year | $ |
|
||||||
| Balance, beginning of year, before effect of changes in the instrument-specific credit risk |
|
|||||||
| Interest accrual |
|
|||||||
| Attributed fees collected |
|
|||||||
| Benefit payments |
(
|
|||||||
| Effect of changes in future assumptions |
|
|||||||
| Effect of changes in interest rates |
(
|
|||||||
| Effect of changes in equity markets |
|
|||||||
| Effect of changes in volatility |
|
|||||||
| Other market impacts |
|
|||||||
| Actual policyholder behavior different from expected behavior |
|
|||||||
| Balance, end of period, before effect of changes in the instrument-specific credit risk |
|
|||||||
| Effect of changes in the instrument-specific credit risk |
(
|
|||||||
| Balance, end of period |
|
|||||||
| Less: reinsurance recoverable |
|
|||||||
| Balance, end of period, after reinsurance | $ |
|
||||||
|
For the year ended December 31, 2021:
|
U.S. and Latin America – Financial Solutions | |||||||
| Balance, beginning of year | $ |
|
||||||
|
Effect of adoption of
Financial Services
–
Insurance
|
|
|||||||
| Adjusted balance, beginning of year |
|
|||||||
| Balance, beginning of year, before effect of changes in the instrument-specific credit risk |
|
|||||||
| Interest accrual |
|
|||||||
| Attributed fees collected |
|
|||||||
| Benefit payments |
(
|
|||||||
| Effect of changes in future assumptions |
|
|||||||
| Effect of changes in interest rates |
(
|
|||||||
| Effect of changes in equity markets |
(
|
|||||||
| Effect of changes in volatility |
(
|
|||||||
| Other market impacts |
|
|||||||
| Actual policyholder behavior different from expected behavior |
|
|||||||
| Balance, end of period, before effect of changes in the instrument-specific credit risk |
|
|||||||
| Effect of changes in the instrument-specific credit risk |
|
|||||||
| Balance, end of period |
|
|||||||
| Less: reinsurance recoverable |
|
|||||||
| Balance, end of period, after reinsurance | $ |
|
||||||
|
For the year ended December 31, 2022:
|
U.S. and Latin America – Traditional | Canada – Traditional | Europe, Middle East and Africa – Traditional | Asia Pacific – Traditional | ||||||||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Capitalization |
|
|
|
|
||||||||||||||||||||||
| Amortization expense |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Foreign currency translation |
|
(
|
(
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
For the year ended December 31, 2022:
|
U.S. and Latin America – Financial Solutions | Canada – Financial Solutions | Europe, Middle East and Africa – Financial Solutions | Asia Pacific – Financial Solutions | ||||||||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Capitalization |
|
|
|
|
||||||||||||||||||||||
| Amortization expense |
(
|
|
|
(
|
||||||||||||||||||||||
| Foreign currency translation |
|
|
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
For the year ended December 31, 2021:
|
U.S. and Latin America – Traditional | Canada – Traditional | Europe, Middle East and Africa – Traditional | Asia Pacific – Traditional | ||||||||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
Effect of adoption of
Financial Services
–
Insurance
|
|
|
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
| Capitalization |
|
|
|
|
||||||||||||||||||||||
| Amortization expense |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Foreign currency translation |
|
|
(
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
For the year ended December 31, 2021:
|
U.S. and Latin America – Financial Solutions | Canada – Financial Solutions | Europe, Middle East and Africa – Financial Solutions | Asia Pacific – Financial Solutions | ||||||||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
Effect of adoption of
Financial Services
–
Insurance
|
|
|
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
| Capitalization |
|
|
|
|
||||||||||||||||||||||
| Amortization expense |
(
|
|
|
(
|
||||||||||||||||||||||
| Foreign currency translation |
|
|
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Three months ended March 31, | ||||||||||||||||||||||||||
| 2023 | 2022 | |||||||||||||||||||||||||
| Earnings: | ||||||||||||||||||||||||||
| Net income | $ |
|
$ |
|
||||||||||||||||||||||
| Less: Net income attributable to noncontrolling interest |
|
|
||||||||||||||||||||||||
| Net income available to RGA, Inc. shareholders | $ |
|
$ |
|
||||||||||||||||||||||
| Shares: | ||||||||||||||||||||||||||
| Weighted average outstanding shares |
|
|
||||||||||||||||||||||||
| Equivalent shares from outstanding stock awards |
|
|
||||||||||||||||||||||||
| Denominator for diluted calculation |
|
|
||||||||||||||||||||||||
| Earnings per share: | ||||||||||||||||||||||||||
| Basic | $ |
|
$ |
|
||||||||||||||||||||||
| Diluted | $ |
|
$ |
|
||||||||||||||||||||||
| Issued | Held In Treasury | Outstanding | ||||||||||||||||||
| Balance, December 31, 2022 |
|
|
|
|||||||||||||||||
| Common stock acquired |
|
|
(
|
|||||||||||||||||
|
Stock-based compensation
(1)
|
|
(
|
|
|||||||||||||||||
| Balance, March 31, 2023 |
|
|
|
|||||||||||||||||
| Issued | Held In Treasury | Outstanding | ||||||||||||||||||
| Balance, December 31, 2021 |
|
|
|
|||||||||||||||||
| Common Stock acquired |
|
|
(
|
|||||||||||||||||
|
Stock-based compensation
(1)
|
|
(
|
|
|||||||||||||||||
| Balance, March 31, 2022 |
|
|
|
|||||||||||||||||
| Accumulated Other Comprehensive Income (Loss), Net of Income Tax | ||||||||||||||||||||||||||||||||||||||
| Foreign Currency Translation Adjustments |
Net Unrealized Investment Gains (Losses)
(1)
|
Pension and
Postretirement Benefits |
Effect of Updating Discount Rates on Future Policy Benefits | Instrument-Specific Credit Risk for Market Risk Benefits | Total | |||||||||||||||||||||||||||||||||
| Balance, December 31, 2022 | $ |
(
|
$ |
(
|
$ |
(
|
$ |
|
$ |
|
$ |
(
|
||||||||||||||||||||||||||
| Other comprehensive income (loss) before reclassifications |
|
|
|
(
|
|
|
||||||||||||||||||||||||||||||||
| Amounts reclassified to (from) AOCI |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Deferred income tax benefit (expense) |
(
|
(
|
(
|
|
(
|
(
|
||||||||||||||||||||||||||||||||
| Balance, March 31, 2023 | $ |
(
|
$ |
(
|
$ |
(
|
$ |
|
$ |
|
$ |
(
|
||||||||||||||||||||||||||
| Accumulated Other Comprehensive Income (Loss), Net of Income Tax | ||||||||||||||||||||||||||||||||||||||
| Foreign Currency Translation Adjustments |
Net Unrealized Investment Gains (Losses)
(1)
|
Pension and
Postretirement Benefits |
Effect of Updating Discount Rates on Future Policy Benefits | Instrument-Specific Credit Risk for Market Risk Benefits | Total | |||||||||||||||||||||||||||||||||
| Balance, December 31, 2021 | $ |
(
|
$ |
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
||||||||||||||||||||||||||
| Other comprehensive income (loss) before reclassifications |
|
(
|
(
|
|
(
|
(
|
||||||||||||||||||||||||||||||||
| Amounts reclassified to (from) AOCI |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Deferred income tax benefit (expense) |
(
|
|
|
(
|
|
|
||||||||||||||||||||||||||||||||
| Balance, March 31, 2022 | $ |
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
$ |
(
|
||||||||||||||||||||||||||
| Amount Reclassified from AOCI | ||||||||||||||||||||||||||||||||||||||
| Three months ended March 31, |
Affected Line Item in
Statements of Income |
|||||||||||||||||||||||||||||||||||||
| Details about AOCI Components | 2023 | 2022 | ||||||||||||||||||||||||||||||||||||
| Net unrealized investment gains (losses): | ||||||||||||||||||||||||||||||||||||||
| Net unrealized gains (losses) on available-for-sale securities | $ |
(
|
$ |
(
|
Investment related gains (losses), net | |||||||||||||||||||||||||||||||||
| Cash flow hedges – Interest rate |
|
|
(1) | |||||||||||||||||||||||||||||||||||
| Cash flow hedges – Currency/Interest rate |
(
|
(
|
(1) | |||||||||||||||||||||||||||||||||||
| Total |
(
|
(
|
||||||||||||||||||||||||||||||||||||
| Provision for income taxes |
|
|
||||||||||||||||||||||||||||||||||||
| Net unrealized gains (losses), net of tax | $ |
(
|
$ |
(
|
||||||||||||||||||||||||||||||||||
| Amortization of defined benefit plan items: | ||||||||||||||||||||||||||||||||||||||
|
Prior service cost (credit)
|
$ |
|
$ |
|
(2) | |||||||||||||||||||||||||||||||||
| Actuarial gains (losses) |
(
|
(
|
(2) | |||||||||||||||||||||||||||||||||||
| Total |
(
|
(
|
||||||||||||||||||||||||||||||||||||
| Provision for income taxes |
|
|
||||||||||||||||||||||||||||||||||||
| Amortization of defined benefit plans, net of tax | $ |
(
|
$ |
(
|
||||||||||||||||||||||||||||||||||
| Total reclassifications for the period | $ |
(
|
$ |
(
|
||||||||||||||||||||||||||||||||||
|
Three months ended March 31, 2023:
|
U.S. and Latin America – Traditional | Canada – Traditional | Europe, Middle East and Africa – Traditional | Asia Pacific – Traditional | ||||||||||||||||||||||
| Present Value of Expected Net Premiums | ||||||||||||||||||||||||||
| Beginning of year balance at original discount rate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Effect of changes in cash flow assumptions |
|
|
|
(
|
||||||||||||||||||||||
| Effect of actual variances from expected experience |
(
|
|
(
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
|
Issuances
(1)
|
|
|
|
|
||||||||||||||||||||||
|
Interest accrual
(2)
|
|
|
|
|
||||||||||||||||||||||
|
Net premiums collected
(3)
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||
|
Derecognition
(4)
|
(
|
|
|
|
||||||||||||||||||||||
| Foreign currency translation |
|
|
|
(
|
||||||||||||||||||||||
| Ending balance at original discount rate |
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Present Value of Expected Future Policy Benefits | ||||||||||||||||||||||||||
| Beginning of year balance at original discount rate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Effect of changes in cash flow assumptions |
|
|
|
(
|
||||||||||||||||||||||
| Effect of actual variances from expected experience |
(
|
|
(
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
|
Issuances
(1)
|
|
|
|
|
||||||||||||||||||||||
|
Interest accrual
(2)
|
|
|
|
|
||||||||||||||||||||||
|
Benefit payments
(5)
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||
|
Derecognition
(4)
|
(
|
|
|
|
||||||||||||||||||||||
| Foreign currency translation |
|
|
|
(
|
||||||||||||||||||||||
| Ending balance at original discount rate |
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Liability for future policy benefits | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Less: reinsurance recoverable |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Net liability for future policy benefits | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Weighted-average duration of the liability (in years) |
|
|
|
|
||||||||||||||||||||||
| Weighted-average interest accretion rate |
|
% |
|
% |
|
% |
|
% | ||||||||||||||||||
| Weighted-average current discount rate |
|
% |
|
% |
|
% |
|
% | ||||||||||||||||||
|
Three months ended March 31, 2022:
|
U.S. and Latin America – Traditional | Canada – Traditional | Europe, Middle East and Africa – Traditional | Asia Pacific – Traditional | ||||||||||||||||||||||
| Present Value of Expected Net Premiums | ||||||||||||||||||||||||||
| Beginning of year balance at original discount rate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Effect of changes in cash flow assumptions |
|
|
|
|
||||||||||||||||||||||
| Effect of actual variances from expected experience |
(
|
|
|
(
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
|
Issuances
(1)
|
|
|
|
|
||||||||||||||||||||||
|
Interest accrual
(2)
|
|
|
|
|
||||||||||||||||||||||
|
Net premiums collected
(3)
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||
|
Derecognition
(4)
|
|
|
|
|
||||||||||||||||||||||
| Foreign currency translation |
|
|
(
|
(
|
||||||||||||||||||||||
| Ending balance at original discount rate |
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
|
(
|
(
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Present Value of Expected Future Policy Benefits | ||||||||||||||||||||||||||
| Beginning of year balance at original discount rate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Effect of changes in cash flow assumptions |
|
|
|
|
||||||||||||||||||||||
| Effect of actual variances from expected experience |
|
|
|
(
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
|
Issuances
(1)
|
|
|
|
|
||||||||||||||||||||||
|
Interest accrual
(2)
|
|
|
|
|
||||||||||||||||||||||
|
Benefit payments
(5)
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||
|
Derecognition
(4)
|
|
|
|
|
||||||||||||||||||||||
| Foreign currency translation |
|
|
(
|
(
|
||||||||||||||||||||||
| Ending balance at original discount rate |
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
|
(
|
(
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Liability for future policy benefits | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Less: reinsurance recoverable |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Net liability for future policy benefits | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Weighted-average duration of the liability (in years) |
|
|
|
|
||||||||||||||||||||||
| Weighted-average interest accretion rate |
|
% |
|
% |
|
% |
|
% | ||||||||||||||||||
| Weighted-average current discount rate |
|
% |
|
% |
|
% |
|
% | ||||||||||||||||||
| Three months ended March 31, 2023: | ||||||||||||||||||||||||||
| Segment | Net liability for future policy benefits at original discount rate | Actual-to-expected variance | Impact of updating discount rate recognized in OCI | Commentary | ||||||||||||||||||||||
|
U.S. and Latin America
–
Traditional
|
$
|
$
|
$
|
During the first quarter of 2023, the Company reviewed the significant assumptions used to measure the liability for future policy benefits and did not make any changes to the segment’s mortality, morbidity, and lapse assumptions as actual experience was consistent with the underlying assumptions. | ||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||
|
Canada
–
Traditional
|
$
|
$
|
$
|
During the first quarter of 2023, the Company reviewed the significant assumptions used to measure the liability for future policy benefits and did not make any changes to the segment’s mortality, morbidity, and lapse assumptions as actual experience was consistent with the underlying assumptions. | ||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||
|
Europe, Middle East and Africa
–
Traditional
|
$
|
$(
|
$(
|
During the first quarter of 2023, the Company reviewed the significant assumptions used to measure the liability for future policy benefits and did not make any material changes to the segment’s mortality, morbidity, and lapse assumptions as actual experience was consistent with the underlying assumptions. | ||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||
|
Asia Pacific
–
Traditional
|
$
|
$(
|
$
|
During the first quarter of 2023, the Company reviewed the significant assumptions used to measure the liability for future policy benefits and did not make any material changes to the segment’s mortality, morbidity, and lapse assumptions as actual experience was consistent with the underlying assumptions. | ||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||
| Three months ended March 31, 2022: | ||||||||||||||||||||||||||
| Segment | Net liability for future policy benefits at original discount rate | Actual-to-expected variance | Impact of updating discount rate recognized in OCI | Commentary | ||||||||||||||||||||||
|
U.S. and Latin America
–
Traditional
|
$
|
$
|
$(
|
During the first quarter of 2022, the Company reviewed the significant assumptions used to measure the liability for future policy benefits and did not make any changes to the segment’s mortality, morbidity, and lapse assumptions as actual experience was consistent with the underlying assumptions. The actual-to-expected variance was predominately related to COVID-19. | ||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||
|
Canada
–
Traditional
|
$
|
$
|
$(
|
During the first quarter of 2022, the Company reviewed the significant assumptions used to measure the liability for future policy benefits and did not make any changes to the segment’s mortality, morbidity, and lapse assumptions as actual experience was consistent with the underlying assumptions. | ||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||
|
Europe, Middle East and Africa
–
Traditional
|
$
|
$(
|
$(
|
During the first quarter of 2022, the Company reviewed the significant assumptions used to measure the liability for future policy benefits and did not make any changes to the segment’s mortality, morbidity, and lapse assumptions as actual experience was consistent with the underlying assumptions. | ||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||
|
Asia Pacific
–
Traditional
|
$
|
$
|
$(
|
During the first quarter of 2022, the Company reviewed the significant assumptions used to measure the liability for future policy benefits and did not make any changes to the segment’s mortality, morbidity, and lapse assumptions as actual experience was consistent with the underlying assumptions. | ||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||
|
Three months ended March 31, 2023:
|
U.S. and Latin America – Financial Solutions | Canada – Financial Solutions | Europe, Middle East and Africa – Financial Solutions | Asia Pacific – Financial Solutions | ||||||||||||||||||||||
| Present Value of Expected Net Premiums | ||||||||||||||||||||||||||
| Beginning of year balance at original discount rate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Effect of changes in cash flow assumptions |
|
|
|
|
||||||||||||||||||||||
| Effect of actual variances from expected experience |
(
|
(
|
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
|
Issuances
(1)
|
|
|
|
|
||||||||||||||||||||||
|
Interest accrual
(2)
|
|
|
|
|
||||||||||||||||||||||
|
Net premiums collected
(3)
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||
|
Derecognition
(4)
|
|
|
|
|
||||||||||||||||||||||
| Foreign currency translation |
|
|
|
(
|
||||||||||||||||||||||
| Ending balance at original discount rate |
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
(
|
(
|
(
|
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Present Value of Expected Future Policy Benefits | ||||||||||||||||||||||||||
| Beginning of year balance at original discount rate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Effect of changes in cash flow assumptions |
|
|
|
|
||||||||||||||||||||||
| Effect of actual variances from expected experience |
(
|
(
|
|
(
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
|
Issuances
(1)
|
|
|
|
|
||||||||||||||||||||||
|
Interest accrual
(2)
|
|
|
|
|
||||||||||||||||||||||
|
Benefit payments
(5)
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||
|
Derecognition
(4)
|
|
|
|
|
||||||||||||||||||||||
| Foreign currency translation |
(
|
|
|
(
|
||||||||||||||||||||||
| Ending balance at original discount rate |
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Liability for future policy benefits | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Less: reinsurance recoverable |
|
|
|
|
||||||||||||||||||||||
| Net liability for future policy benefits | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Weighted-average duration of the liability (in years) |
|
|
|
|
||||||||||||||||||||||
| Weighted-average interest accretion rate |
|
% |
|
% |
|
% |
|
% | ||||||||||||||||||
| Weighted-average current discount rate |
|
% |
|
% |
|
% |
|
% | ||||||||||||||||||
|
Three months ended March 31, 2022:
|
U.S. and Latin America – Financial Solutions | Canada – Financial Solutions | Europe, Middle East and Africa – Financial Solutions | Asia Pacific – Financial Solutions | ||||||||||||||||||||||
| Present Value of Expected Net Premiums | ||||||||||||||||||||||||||
| Beginning of year balance at original discount rate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Effect of changes in cash flow assumptions |
|
|
|
|
||||||||||||||||||||||
| Effect of actual variances from expected experience |
(
|
(
|
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
|
Issuances
(1)
|
|
|
|
|
||||||||||||||||||||||
|
Interest accrual
(2)
|
|
|
|
|
||||||||||||||||||||||
|
Net premiums collected
(3)
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||
|
Derecognition
(4)
|
|
|
|
|
||||||||||||||||||||||
| Foreign currency translation |
|
|
(
|
(
|
||||||||||||||||||||||
| Ending balance at original discount rate |
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
(
|
(
|
(
|
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Present Value of Expected Future Policy Benefits | ||||||||||||||||||||||||||
| Beginning of year balance at original discount rate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Effect of changes in cash flow assumptions |
|
|
|
|
||||||||||||||||||||||
| Effect of actual variances from expected experience |
(
|
(
|
|
|
||||||||||||||||||||||
| Adjusted balance, beginning of year |
|
|
|
|
||||||||||||||||||||||
|
Issuances
(1)
|
|
|
|
|
||||||||||||||||||||||
|
Interest accrual
(2)
|
|
|
|
|
||||||||||||||||||||||
|
Benefit payments
(5)
|
(
|
(
|
(
|
(
|
||||||||||||||||||||||
|
Derecognition
(4)
|
|
|
|
|
||||||||||||||||||||||
| Foreign currency translation |
|
|
(
|
(
|
||||||||||||||||||||||
| Ending balance at original discount rate |
|
|
|
|
||||||||||||||||||||||
| Effect of changes in discount rate assumptions |
|
(
|
(
|
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Liability for future policy benefits | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Less: reinsurance recoverable |
|
|
|
|
||||||||||||||||||||||
| Net liability for future policy benefits | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Weighted-average duration of the liability (in years) |
|
|
|
|
||||||||||||||||||||||
| Weighted-average interest accretion rate |
|
% |
|
% |
|
% |
|
% | ||||||||||||||||||
| Weighted-average current discount rate |
|
% |
|
% |
|
% |
|
% | ||||||||||||||||||
| Three months ended March 31, 2023: | ||||||||||||||||||||||||||
| Segment | Net liability for future policy benefits at original discount rate | Actual-to-expected variance |
Impact of updating discount rate recognized in OCI
|
Commentary | ||||||||||||||||||||||
|
U.S. and Latin America
–
Financial Solutions
|
$
|
$(
|
$
|
During the first quarter of 2023, the Company reviewed the significant assumptions used to measure the liability for future policy benefits and did not make any changes to the segment’s mortality, morbidity, and lapse assumptions as actual experience was consistent with the underlying assumptions. | ||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||
|
Canada
–
Financial Solutions
|
$
|
$(
|
$
|
During the first quarter of 2023, the Company reviewed the significant assumptions used to measure the liability for future policy benefits and did not make any changes to the segment’s mortality, morbidity, and lapse assumptions as actual experience was consistent with the underlying assumptions. | ||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||
|
Europe, Middle East and Africa
–
Financial Solutions
|
$
|
$(
|
$
|
During the first quarter of 2023, the Company reviewed the significant assumptions used to measure the liability for future policy benefits and did not make any changes to the segment’s mortality, morbidity, and lapse assumptions as actual experience was consistent with the underlying assumptions. | ||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||
|
Asia Pacific
–
Financial Solutions
|
$
|
$(
|
$
|
During the first quarter of 2023, the Company reviewed the significant assumptions used to measure the liability for future policy benefits and did not make any changes to the segment’s mortality, morbidity, and lapse assumptions as actual experience was consistent with the underlying assumptions. | ||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||
| For the three months ended March 31, 2022: | ||||||||||||||||||||||||||
| Segment | Net liability for future policy benefits at original discount rate | Actual-to-expected variance | Impact of updating discount rate recognized in OCI | Commentary | ||||||||||||||||||||||
|
U.S. and Latin America
–
Financial Solutions
|
$
|
$(
|
$(
|
During the first quarter of 2022, the Company reviewed the significant assumptions used to measure the liability for future policy benefits and did not make any changes to the segment’s mortality, morbidity, and lapse assumptions as actual experience was consistent with the underlying assumptions. | ||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||
|
Canada
–
Financial Solutions
|
$
|
$(
|
$(
|
During the first quarter of 2022, the Company reviewed the significant assumptions used to measure the liability for future policy benefits and did not make any changes to the segment’s mortality, morbidity, and lapse assumptions as actual experience was consistent with the underlying assumptions. | ||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||
|
Europe, Middle East and Africa
–
Financial Solutions
|
$
|
$(
|
$(
|
During the first quarter of 2022, the Company reviewed the significant assumptions used to measure the liability for future policy benefits and did not make any changes to the segment’s mortality, morbidity, and lapse assumptions as actual experience was consistent with the underlying assumptions. | ||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||
|
Asia Pacific
–
Financial Solutions
|
$
|
$
|
$(
|
During the first quarter of 2022, the Company reviewed the significant assumptions used to measure the liability for future policy benefits and did not make any changes to the segment’s mortality, morbidity, and lapse assumptions as actual experience was consistent with the underlying assumptions. | ||||||||||||||||||||||
|
|
|
|
||||||||||||||||||||||||
| March 31, | ||||||||||||||
| 2023 | 2022 | |||||||||||||
| Liability for future policy benefits included in the rollforwards: | ||||||||||||||
| Traditional: | ||||||||||||||
| U.S. and Latin America | $ |
|
$ |
|
||||||||||
| Canada |
|
|
||||||||||||
| Europe, Middle East and Africa |
|
|
||||||||||||
| Asia Pacific |
|
|
||||||||||||
| Financial Solutions: | ||||||||||||||
| U.S. and Latin America |
|
|
||||||||||||
| Canada |
|
|
||||||||||||
| Europe, Middle East and Africa |
|
|
||||||||||||
| Asia Pacific |
|
|
||||||||||||
| Other long-duration contracts |
|
|
||||||||||||
| Claims liability and incurred but not reported claims |
|
|
||||||||||||
| Unearned revenue liability |
|
|
||||||||||||
| Total liability for future policy benefits | $ |
|
$ |
|
||||||||||
| March 31, | ||||||||||||||||||||||||||
|
2023
|
2022 | |||||||||||||||||||||||||
| Undiscounted | Discounted | Undiscounted | Discounted | |||||||||||||||||||||||
| Expected future gross premiums | ||||||||||||||||||||||||||
| Traditional: | ||||||||||||||||||||||||||
| U.S. and Latin America | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Canada |
|
|
|
|
||||||||||||||||||||||
| Europe, Middle East and Africa |
|
|
|
|
||||||||||||||||||||||
| Asia Pacific |
|
|
|
|
||||||||||||||||||||||
| Financial Solutions: | ||||||||||||||||||||||||||
| U.S. and Latin America |
|
|
|
|
||||||||||||||||||||||
| Canada |
|
|
|
|
||||||||||||||||||||||
| Europe, Middle East and Africa |
|
|
|
|
||||||||||||||||||||||
| Asia Pacific |
|
|
|
|
||||||||||||||||||||||
| Expected future benefit payments | ||||||||||||||||||||||||||
| Traditional: | ||||||||||||||||||||||||||
| U.S. and Latin America | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Canada |
|
|
|
|
||||||||||||||||||||||
| Europe, Middle East and Africa |
|
|
|
|
||||||||||||||||||||||
| Asia Pacific |
|
|
|
|
||||||||||||||||||||||
| Financial Solutions: | ||||||||||||||||||||||||||
| U.S. and Latin America |
|
|
|
|
||||||||||||||||||||||
| Canada |
|
|
|
|
||||||||||||||||||||||
| Europe, Middle East and Africa |
|
|
|
|
||||||||||||||||||||||
| Asia Pacific |
|
|
|
|
||||||||||||||||||||||
| Gross Premiums | Interest Expense | |||||||||||||||||||||||||
| March 31, | March 31, | |||||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||
| Traditional: | ||||||||||||||||||||||||||
| U.S. and Latin America | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Canada |
|
|
|
|
||||||||||||||||||||||
| Europe, Middle East and Africa |
|
|
|
|
||||||||||||||||||||||
| Asia Pacific |
|
|
|
|
||||||||||||||||||||||
| Financial Solutions: | ||||||||||||||||||||||||||
| U.S. and Latin America |
|
|
|
|
||||||||||||||||||||||
| Canada |
|
|
|
|
||||||||||||||||||||||
| Europe, Middle East and Africa |
|
|
|
|
||||||||||||||||||||||
| Asia Pacific |
|
|
|
|
||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
Three months ended March 31, 2023:
|
U.S. and Latin America – Traditional | U.S. and Latin America – Financial Solutions | Asia Pacific – Financial Solutions | |||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
||||||||||||||
| Deposits |
|
|
|
|||||||||||||||||
| Policy charges |
(
|
(
|
|
|||||||||||||||||
| Surrenders and withdrawals |
(
|
(
|
(
|
|||||||||||||||||
| Benefit payments |
(
|
(
|
(
|
|||||||||||||||||
| Interest credited |
|
|
|
|||||||||||||||||
| Foreign currency translation |
|
|
(
|
|||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
||||||||||||||
| Less: reinsurance recoverable |
|
(
|
|
|||||||||||||||||
| Balance, end of period, after reinsurance | $ |
|
$ |
|
$ |
|
||||||||||||||
| Weighted-average crediting rate |
|
% |
|
% |
|
% | ||||||||||||||
| Net amount at risk | $ |
|
$ |
|
$ |
|
||||||||||||||
| Cash surrender value | $ |
|
$ |
|
$ |
|
||||||||||||||
|
Three months ended March 31, 2022:
|
U.S. and Latin America – Traditional | U.S. and Latin America – Financial Solutions | Asia Pacific – Financial Solutions | |||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
||||||||||||||
| Deposits |
|
|
|
|||||||||||||||||
| Policy charges |
(
|
(
|
(
|
|||||||||||||||||
| Surrenders and withdrawals |
(
|
(
|
(
|
|||||||||||||||||
| Benefit payments |
(
|
(
|
(
|
|||||||||||||||||
| Interest credited |
|
|
|
|||||||||||||||||
| Foreign currency translation |
|
|
|
|||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
||||||||||||||
| Less: reinsurance recoverable |
|
(
|
|
|||||||||||||||||
| Balance, end of period, after reinsurance | $ |
|
$ |
|
$ |
|
||||||||||||||
| Weighted-average crediting rate |
|
% |
|
% |
|
% | ||||||||||||||
| Net amount at risk | $ |
|
$ |
|
$ |
|
||||||||||||||
| Cash surrender value | $ |
|
$ |
|
$ |
|
||||||||||||||
| March 31, | ||||||||||||||
| 2023 | 2022 | |||||||||||||
| Policyholder account balances included in the rollforwards: | ||||||||||||||
| Traditional: | ||||||||||||||
| U.S. and Latin America | $ |
|
$ |
|
||||||||||
| Financial Solutions: | ||||||||||||||
| U.S. and Latin America |
|
|
||||||||||||
| Asia Pacific |
|
|
||||||||||||
| Other policyholder account balances | ||||||||||||||
| U.S. and Latin America – Financial Solutions |
|
|
||||||||||||
| Total policyholder account balances | $ |
|
$ |
|
||||||||||
|
March 31, 2023
|
||||||||||||||||||||||||||||||||||||||
| Range of Guaranteed Minimum Crediting Rate | At Guaranteed Minimum | 1 Basis Point – 50 Basis Points Above | 51 Basis Points – 150 Basis Points Above | Greater Than 150 Basis Points Above | Total | |||||||||||||||||||||||||||||||||
| U.S. and Latin America – Traditional | Less than 1.00% | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| 1.00 – 1.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 2.00 – 2.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 3.00 – 3.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 4.00% and Greater |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||
| U.S. and Latin America – Financial Solutions | Less than 1.00% | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| 1.00 – 1.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 2.00 – 2.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 3.00 – 3.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 4.00% and Greater |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||
| Asia Pacific – Financial Solutions | Less than 1.00% | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| 1.00 – 1.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 2.00 – 2.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 3.00 – 3.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 4.00% and Greater |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||
|
March 31, 2022
|
||||||||||||||||||||||||||||||||||||||
| Range of Guaranteed Minimum Crediting Rate | At Guaranteed Minimum | 1 Basis Point – 50 Basis Points Above | 51 Basis Points – 150 Basis Points Above | Greater Than 150 Basis Points Above | Total | |||||||||||||||||||||||||||||||||
| U.S. and Latin America – Traditional | Less than 1.00% | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| 1.00 – 1.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 2.00 – 2.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 3.00 – 3.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 4.00% and Greater |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||
| U.S. and Latin America – Financial Solutions | Less than 1.00% | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| 1.00 – 1.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 2.00 – 2.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 3.00 – 3.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 4.00% and Greater |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||
| Asia Pacific – Financial Solutions | Less than 1.00% | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| 1.00 – 1.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 2.00 – 2.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 3.00 – 3.99% |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| 4.00% and Greater |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||
| Three months ended March 31, | ||||||||||||||
| 2023 | 2022 | |||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
||||||||||
| Less: reinsurance recoverable |
(
|
(
|
||||||||||||
| Net balance, beginning of year |
|
|
||||||||||||
| Incurred: | ||||||||||||||
| Current year |
|
|
||||||||||||
| Prior years |
(
|
(
|
||||||||||||
| Total incurred |
|
|
||||||||||||
| Payments: | ||||||||||||||
| Current year |
(
|
(
|
||||||||||||
| Prior years |
(
|
(
|
||||||||||||
| Total payments |
(
|
(
|
||||||||||||
| Other changes: | ||||||||||||||
| Interest accretion |
|
|
||||||||||||
| Foreign exchange adjustments |
(
|
|
||||||||||||
| Total other changes |
|
|
||||||||||||
| Net balance, end of period |
|
|
||||||||||||
| Plus: reinsurance recoverable |
|
|
||||||||||||
| Balance, end of period | $ |
|
$ |
|
||||||||||
| U.S. and Latin America – Financial Solutions | ||||||||||||||
| Three months ended March 31, | ||||||||||||||
| 2023 | 2022 | |||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
||||||||||
| Balance, beginning of year, before effect of changes in the instrument-specific credit risk |
|
|
||||||||||||
| Interest accrual |
|
|
||||||||||||
| Attributed fees collected |
|
|
||||||||||||
| Benefit payments |
|
(
|
||||||||||||
| Effect of changes in interest rates |
|
(
|
||||||||||||
| Effect of changes in equity markets |
(
|
|
||||||||||||
| Effect of changes in volatility |
(
|
|
||||||||||||
| Other market impacts |
|
|
||||||||||||
| Actual policyholder behavior different from expected behavior |
|
|
||||||||||||
| Balance, end of period, before effect of changes in the instrument-specific credit risk |
|
|
||||||||||||
| Effect of changes in the instrument-specific credit risk |
(
|
|
||||||||||||
| Balance, end of period |
|
|
||||||||||||
| Less: reinsurance recoverable |
|
|
||||||||||||
| Balance, end of period, after reinsurance | $ |
|
$ |
|
||||||||||
| Net amount at risk | $ |
|
$ |
|
||||||||||
| Weighted-average attained age of contract holders (in years) |
|
|
||||||||||||
| March 31, | March 31, | |||||||||||||||||||||||||||||||||||||
| 2023 | 2022 | |||||||||||||||||||||||||||||||||||||
|
Asset
(1)
|
Liability | Net |
Asset
(1)
|
Liability | Net | |||||||||||||||||||||||||||||||||
| U.S. and Latin America – Financial Solutions | $ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
(
|
||||||||||||||||||||||||||
| Total market risk benefits | $ |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
$ |
(
|
||||||||||||||||||||||||||
|
Three months ended March 31, 2023:
|
U.S. and Latin America – Traditional | Canada – Traditional | Europe, Middle East and Africa – Traditional | Asia Pacific – Traditional | ||||||||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Capitalization |
|
|
|
|
||||||||||||||||||||||
| Amortization expense |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Foreign currency translation |
|
|
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
Three months ended March 31, 2022:
|
U.S. and Latin America – Traditional | Canada – Traditional | Europe, Middle East and Africa – Traditional | Asia Pacific – Traditional | ||||||||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Capitalization |
|
|
|
|
||||||||||||||||||||||
| Amortization expense |
(
|
(
|
(
|
(
|
||||||||||||||||||||||
| Foreign currency translation |
|
|
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
Three months ended March 31, 2023:
|
U.S. and Latin America – Financial Solutions | Canada – Financial Solutions | Europe, Middle East and Africa – Financial Solutions | Asia Pacific – Financial Solutions | ||||||||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Capitalization |
|
|
|
|
||||||||||||||||||||||
| Amortization expense |
(
|
|
|
(
|
||||||||||||||||||||||
| Foreign currency translation |
|
|
|
(
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
|
Three months ended March 31, 2022:
|
U.S. and Latin America – Financial Solutions | Canada – Financial Solutions | Europe, Middle East and Africa – Financial Solutions | Asia Pacific – Financial Solutions | ||||||||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Capitalization |
|
|
|
|
||||||||||||||||||||||
| Amortization expense |
(
|
|
|
(
|
||||||||||||||||||||||
| Foreign currency translation |
|
|
|
|
||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| March 31, | ||||||||||||||
| 2023 | 2022 | |||||||||||||
| Deferred policy acquisition costs included in the rollforwards: | ||||||||||||||
| Traditional: | ||||||||||||||
| U.S. and Latin America | $ |
|
$ |
|
||||||||||
| Canada |
|
|
||||||||||||
| Europe, Middle East and Africa |
|
|
||||||||||||
| Asia Pacific |
|
|
||||||||||||
| Financial Solutions: | ||||||||||||||
| U.S. and Latin America |
|
|
||||||||||||
| Canada |
|
|
||||||||||||
| Europe, Middle East and Africa |
|
|
||||||||||||
| Asia Pacific |
|
|
||||||||||||
| Other long-duration business: | ||||||||||||||
| Corporate and Other |
|
|
||||||||||||
| Total deferred policy acquisition costs | $ |
|
$ |
|
||||||||||
| March 31, 2023: | Amortized | Allowance for | Unrealized | Unrealized | Estimated Fair | % of | ||||||||||||||||||||||||||||||||||||||
| Cost | Credit Losses | Gains | Losses | Value | Total | |||||||||||||||||||||||||||||||||||||||
| Available-for-sale: | ||||||||||||||||||||||||||||||||||||||||||||
| Corporate | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|
% | ||||||||||||||||||||||||||||||||
| Canadian government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||
| Japanese government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||
| ABS |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||
| CMBS |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||
| RMBS |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||
| U.S. government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||
| State and political subdivisions |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||
| Other foreign government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||
| Total fixed maturity securities | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|
% | ||||||||||||||||||||||||||||||||
| December 31, 2022: | Amortized | Allowance for | Unrealized | Unrealized | Estimated Fair | % of | ||||||||||||||||||||||||||||||||
| Cost | Credit Losses | Gains | Losses | Value | Total | |||||||||||||||||||||||||||||||||
| Available-for-sale: | ||||||||||||||||||||||||||||||||||||||
| Corporate | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|
% | ||||||||||||||||||||||||||
| Canadian government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Japanese government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| ABS |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| CMBS |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| RMBS |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| U.S. government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| State and political subdivisions |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Other foreign government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Total fixed maturity securities | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|
% | ||||||||||||||||||||||||||
| March 31, 2023 | December 31, 2022 | ||||||||||||||||||||||
|
Amortized
Cost |
Estimated
Fair Value |
Amortized
Cost |
Estimated
Fair Value |
||||||||||||||||||||
| Fixed maturity securities pledged as collateral | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Fixed maturity securities received as collateral | n/a |
|
n/a |
|
|||||||||||||||||||
| Assets in trust held to satisfy collateral requirements |
|
|
|
|
|||||||||||||||||||
| March 31, 2023 | December 31, 2022 | ||||||||||||||||||||||
|
Amortized
Cost |
Estimated
Fair Value |
Amortized
Cost |
Estimated
Fair Value |
||||||||||||||||||||
| Fixed maturity securities guaranteed or issued by: | |||||||||||||||||||||||
| Canadian province of Quebec | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
| Canadian province of Ontario |
|
|
|
|
|||||||||||||||||||
| Amortized Cost | Estimated Fair Value | |||||||||||||
| Available-for-sale: | ||||||||||||||
| Due in one year or less | $ |
|
$ |
|
||||||||||
| Due after one year through five years |
|
|
||||||||||||
| Due after five years through ten years |
|
|
||||||||||||
| Due after ten years |
|
|
||||||||||||
| Structured securities |
|
|
||||||||||||
| Total | $ |
|
$ |
|
||||||||||
| March 31, 2023: | Estimated | |||||||||||||||||||
| Amortized Cost | Fair Value | % of Total | ||||||||||||||||||
| Finance | $ |
|
$ |
|
|
% | ||||||||||||||
| Industrial |
|
|
|
|||||||||||||||||
| Utility |
|
|
|
|||||||||||||||||
| Total | $ |
|
$ |
|
|
% | ||||||||||||||
| December 31, 2022: | Estimated | |||||||||||||||||||
| Amortized Cost | Fair Value | % of Total | ||||||||||||||||||
| Finance | $ |
|
$ |
|
|
% | ||||||||||||||
| Industrial |
|
|
|
|||||||||||||||||
| Utility |
|
|
|
|||||||||||||||||
| Total | $ |
|
$ |
|
|
% | ||||||||||||||
|
For the three months ended March 31, 2023:
|
|||||||||||||||||||||||||||||||||||
| Corporate | ABS | CMBS | Other Foreign Government | Total | |||||||||||||||||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||
| Credit losses recognized on securities for which credit losses were not previously recorded |
|
|
|
|
|
||||||||||||||||||||||||||||||
| Reductions for securities sold during the period |
(
|
|
|
|
(
|
||||||||||||||||||||||||||||||
| Additional increases or decreases for credit losses on securities that had an allowance recorded in a previous period |
|
|
|
|
|
||||||||||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||
|
For the three months ended March 31, 2022:
|
|||||||||||||||||||||||||||||
| Corporate | ABS | CMBS | Other Foreign Government | Total | |||||||||||||||||||||||||
| Balance, beginning of year | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
| Credit losses recognized on securities for which credit losses were not previously recorded |
|
|
|
|
|
||||||||||||||||||||||||
| Reductions for securities sold during the period |
(
|
|
|
(
|
(
|
||||||||||||||||||||||||
| Additional increases or decreases for credit losses on securities that had an allowance recorded in a previous period |
|
|
|
|
|
||||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
| Less than 12 months | 12 months or greater | Total | ||||||||||||||||||||||||||||||||||||
| Gross | Gross | Gross | ||||||||||||||||||||||||||||||||||||
| March 31, 2023: | Estimated | Unrealized | Estimated | Unrealized | Estimated | Unrealized | ||||||||||||||||||||||||||||||||
| Fair Value | Losses | Fair Value | Losses | Fair Value | Losses | |||||||||||||||||||||||||||||||||
| Investment grade securities: | ||||||||||||||||||||||||||||||||||||||
| Corporate | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||
| Canadian government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Japanese government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| ABS |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| CMBS |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| RMBS |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| U.S. government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| State and political subdivisions |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Other foreign government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Total investment grade securities |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
|
Below investment grade securities:
|
||||||||||||||||||||||||||||||||||||||
| Corporate |
|
|
|
|
|
$ |
|
|||||||||||||||||||||||||||||||
| ABS |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Other foreign government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Total below investment grade securities |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Total fixed maturity securities | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||
| Less than 12 months | 12 months or greater | Total | ||||||||||||||||||||||||||||||||||||
| Gross | Gross | Gross | ||||||||||||||||||||||||||||||||||||
| December 31, 2022: | Estimated | Unrealized | Estimated | Unrealized | Estimated | Unrealized | ||||||||||||||||||||||||||||||||
| Fair Value | Losses | Fair Value | Losses | Fair Value | Losses | |||||||||||||||||||||||||||||||||
| Investment grade securities: | ||||||||||||||||||||||||||||||||||||||
| Corporate | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||
| Canadian government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Japanese government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| ABS |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| CMBS |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| RMBS |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| U.S. government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| State and political subdivisions |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Other foreign government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Total investment grade securities |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Below investment grade securities: | ||||||||||||||||||||||||||||||||||||||
| Corporate |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| ABS |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Other foreign government |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Total below investment grade securities |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Total fixed maturity securities | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||
| Three months ended March 31, | ||||||||||||||||||||||||||
| 2023 | 2022 | |||||||||||||||||||||||||
| Fixed maturity securities available-for-sale | $ |
|
$ |
|
||||||||||||||||||||||
| Equity securities |
|
|
||||||||||||||||||||||||
| Mortgage loans |
|
|
||||||||||||||||||||||||
| Policy loans |
|
|
||||||||||||||||||||||||
| Funds withheld at interest |
|
|
||||||||||||||||||||||||
| Limited partnerships and real estate joint ventures |
|
|
||||||||||||||||||||||||
| Short-term investments and cash and cash equivalents |
|
|
||||||||||||||||||||||||
| Other invested assets |
|
|
||||||||||||||||||||||||
| Investment income |
|
|
||||||||||||||||||||||||
| Investment expense |
(
|
(
|
||||||||||||||||||||||||
| Net investment income | $ |
|
$ |
|
||||||||||||||||||||||
| Three months ended March 31, | |||||||||||||||||||||||
| 2023 | 2022 | ||||||||||||||||||||||
| Fixed maturity securities available-for-sale: | |||||||||||||||||||||||
| Change in allowance for credit losses | $ |
(
|
$ |
(
|
|||||||||||||||||||
| Impairments on fixed maturities |
(
|
(
|
|||||||||||||||||||||
| Realized gains on investment activity |
|
|
|||||||||||||||||||||
| Realized losses on investment activity |
(
|
(
|
|||||||||||||||||||||
| Net gains (losses) on equity securities |
|
(
|
|||||||||||||||||||||
| Change in mortgage loan allowance for credit losses |
|
(
|
|||||||||||||||||||||
| Change in fair value of certain limited partnership investments |
(
|
|
|||||||||||||||||||||
| Other, net |
|
|
|||||||||||||||||||||
| Net gains (losses) on derivatives |
|
(
|
|||||||||||||||||||||
| Total investment related gains (losses), net | $ |
(
|
$ |
(
|
|||||||||||||||||||
| March 31, 2023 | December 31, 2022 | ||||||||||||||||||||||
|
Amortized
Cost |
Estimated
Fair Value |
Amortized
Cost |
Estimated
Fair Value |
||||||||||||||||||||
| Securities borrowing agreements: | |||||||||||||||||||||||
|
Securities borrowed
(1)
|
n/a | $ |
|
n/a | $ |
|
|||||||||||||||||
|
Securities pledged as collateral
(2)
|
|
|
|
|
|||||||||||||||||||
| Securities lending agreements: | |||||||||||||||||||||||
|
Securities loaned
(2)
|
|
|
|
|
|||||||||||||||||||
|
Securities received as collateral
(3)
|
n/a |
|
n/a |
|
|||||||||||||||||||
| Repurchase/reverse repurchase agreements: | |||||||||||||||||||||||
|
Securities sold
(2)
|
|
|
|
|
|||||||||||||||||||
|
Securities purchased
(3)
|
n/a |
|
n/a |
|
|||||||||||||||||||
|
Cash received
(4)
|
|
|
|
|
|||||||||||||||||||
| March 31, 2023 | |||||||||||||||||||||||||||||
| Remaining Contractual Maturity of the Agreements | |||||||||||||||||||||||||||||
| Overnight and Continuous | Up to 30 Days | 30 – 90 Days | Greater than 90 Days | Total | |||||||||||||||||||||||||
| Securities lending agreements: | |||||||||||||||||||||||||||||
| Corporate | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
| Canadian government |
|
|
|
|
|
||||||||||||||||||||||||
| State and political subdivisions |
|
|
|
|
|
||||||||||||||||||||||||
| Other foreign government |
|
|
|
|
|
||||||||||||||||||||||||
| Total |
|
|
|
|
|
||||||||||||||||||||||||
| Repurchase agreements: | |||||||||||||||||||||||||||||
| Corporate |
|
|
|
|
|
||||||||||||||||||||||||
| Japanese government |
|
|
|
|
|
||||||||||||||||||||||||
| ABS |
|
|
|
|
|
||||||||||||||||||||||||
| CMBS |
|
|
|
|
|
||||||||||||||||||||||||
| RMBS |
|
|
|
|
|
||||||||||||||||||||||||
| U.S. government |
|
|
|
|
|
||||||||||||||||||||||||
| Other foreign government |
|
|
|
|
|
||||||||||||||||||||||||
| Total |
|
|
|
|
|
||||||||||||||||||||||||
| Total agreements | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
| December 31, 2022 | |||||||||||||||||||||||||||||
| Remaining Contractual Maturity of the Agreements | |||||||||||||||||||||||||||||
| Overnight and Continuous | Up to 30 Days | 30 – 90 Days | Greater than 90 Days | Total | |||||||||||||||||||||||||
| Securities lending agreements: | |||||||||||||||||||||||||||||
| Corporate | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
| Canadian government |
|
|
|
|
|
||||||||||||||||||||||||
| State and political subdivisions |
|
|
|
|
|
||||||||||||||||||||||||
| Other foreign government |
|
|
|
|
|
||||||||||||||||||||||||
| Total |
|
|
|
|
|
||||||||||||||||||||||||
| Repurchase agreements: | |||||||||||||||||||||||||||||
| Corporate |
|
|
|
|
|
||||||||||||||||||||||||
| Japanese government |
|
|
|
|
|
||||||||||||||||||||||||
| ABS |
|
|
|
|
|
||||||||||||||||||||||||
| CMBS |
|
|
|
|
|
||||||||||||||||||||||||
| RMBS |
|
|
|
|
|
||||||||||||||||||||||||
| U.S. government |
|
|
|
|
|
||||||||||||||||||||||||
| Other foreign government |
|
|
|
|
|
||||||||||||||||||||||||
| Total |
|
|
|
|
|
||||||||||||||||||||||||
| Total agreements | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||
| March 31, 2023 | December 31, 2022 | |||||||||||||||||||||||||
| Property type: | Carrying Value | % of Total | Carrying Value | % of Total | ||||||||||||||||||||||
| Office | $ |
|
|
% | $ |
|
|
% | ||||||||||||||||||
| Retail |
|
|
|
|
||||||||||||||||||||||
| Industrial |
|
|
|
|
||||||||||||||||||||||
| Apartment |
|
|
|
|
||||||||||||||||||||||
| Other commercial |
|
|
|
|
||||||||||||||||||||||
| Recorded investment |
|
|
% |
|
|
% | ||||||||||||||||||||
| Unamortized balance of loan origination fees and expenses |
(
|
(
|
||||||||||||||||||||||||
| Allowance for credit losses |
(
|
(
|
||||||||||||||||||||||||
| Total mortgage loans | $ |
|
$ |
|
||||||||||||||||||||||
| March 31, 2023 | December 31, 2022 | |||||||||||||||||||||||||
|
Recorded
Investment |
% of Total |
Recorded
Investment |
% of Total | |||||||||||||||||||||||
| Due within five years | $ |
|
|
% | $ |
|
|
% | ||||||||||||||||||
| Due after five years through ten years |
|
|
|
|
||||||||||||||||||||||
| Due after ten years |
|
|
|
|
||||||||||||||||||||||
| Total | $ |
|
|
% | $ |
|
|
% | ||||||||||||||||||
| Recorded Investment | |||||||||||||||||||||||||||||||||||
| Debt Service Ratios | Construction loans | ||||||||||||||||||||||||||||||||||
| >1.20x | 1.00x – 1.20x | <1.00x | Total | % of Total | |||||||||||||||||||||||||||||||
| March 31, 2023: | |||||||||||||||||||||||||||||||||||
| Loan-to-Value Ratio | |||||||||||||||||||||||||||||||||||
| 0% – 59.99% | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|
% | |||||||||||||||||||||||
| 60% – 69.99% |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| 70% – 79.99% |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| 80% or greater |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|
% | |||||||||||||||||||||||
| Recorded Investment | |||||||||||||||||||||||||||||||||||
| Debt Service Ratios | Construction loans | ||||||||||||||||||||||||||||||||||
| >1.20x | 1.00x – 1.20x | <1.00x | Total | % of Total | |||||||||||||||||||||||||||||||
| December 31, 2022: | |||||||||||||||||||||||||||||||||||
| Loan-to-Value Ratio | |||||||||||||||||||||||||||||||||||
| 0% – 59.99% | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|
% | |||||||||||||||||||||||
| 60% – 69.99% |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| 70% – 79.99% |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| 80% or greater |
|
|
|
|
|
|
|||||||||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|
% | |||||||||||||||||||||||
| Recorded Investment | |||||||||||||||||||||||||||||||||||||||||
| Year of Origination | |||||||||||||||||||||||||||||||||||||||||
| 2023 | 2022 | 2021 | 2020 | 2019 | Prior | Total | |||||||||||||||||||||||||||||||||||
| March 31, 2023: | |||||||||||||||||||||||||||||||||||||||||
| Internal credit quality grade: | |||||||||||||||||||||||||||||||||||||||||
| High investment grade | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| Investment grade |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Average |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Watch list |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| In or near default |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| Recorded Investment | |||||||||||||||||||||||||||||||||||||||||
| Year of Origination | |||||||||||||||||||||||||||||||||||||||||
| 2022 | 2021 | 2020 | 2019 | 2018 | Prior | Total | |||||||||||||||||||||||||||||||||||
| December 31, 2022: | |||||||||||||||||||||||||||||||||||||||||
| Internal credit quality grade: | |||||||||||||||||||||||||||||||||||||||||
| High investment grade | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| Investment grade |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Average |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Watch list |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| In or near default |
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||
| March 31, 2023 | December 31, 2022 | |||||||||||||
| Current | $ |
|
$ |
|
||||||||||
| 31 – 60 days past due |
|
|
||||||||||||
|
Greater than 90 days past due
|
|
|
||||||||||||
| Total | $ |
|
$ |
|
||||||||||
| Three months ended March 31, | ||||||||||||||||||||||||||
| 2023 | 2022 | |||||||||||||||||||||||||
| Balance, beginning of period | $ |
|
$ |
|
||||||||||||||||||||||
| Change in allowance for credit losses |
(
|
|
||||||||||||||||||||||||
| Balance, end of period | $ |
|
$ |
|
||||||||||||||||||||||
| March 31, 2023 | December 31, 2022 | |||||||||||||
| Limited partnerships – equity method | $ |
|
$ |
|
||||||||||
| Limited partnerships – fair value |
|
|
||||||||||||
| Limited partnerships – cost method |
|
|
||||||||||||
| Real estate joint ventures |
|
|
||||||||||||
| Total limited partnerships and real estate joint ventures | $ |
|
$ |
|
||||||||||
| March 31, 2023 | December 31, 2022 | |||||||||||||
| Lifetime mortgages | $ |
|
$ |
|
||||||||||
| Derivatives |
|
|
||||||||||||
| Other |
|
|
||||||||||||
| Total other invested assets | $ |
|
$ |
|
||||||||||
| March 31, 2023 | December 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||
| Primary Underlying Risk | Notional | Carrying Value/Fair Value | Notional | Carrying Value/Fair Value | ||||||||||||||||||||||||||||||||||||||||
| Amount | Assets | Liabilities | Amount | Assets | Liabilities | |||||||||||||||||||||||||||||||||||||||
| Derivatives not designated as hedging instruments: | ||||||||||||||||||||||||||||||||||||||||||||
| Interest rate swaps | Interest rate | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||||||||||||||||||
| Interest rate options | Interest rate |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||
| Total return swaps | Interest rate |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||
| Interest rate futures | Interest rate |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||
| Equity futures | Equity |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||
| Foreign currency swaps | Foreign currency |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||
| Foreign currency forwards | Foreign currency |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||
| CPI swaps | CPI |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||
| Credit default swaps | Credit |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||
| Equity options | Equity |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||
| Synthetic GICs | Interest rate |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||
| Embedded derivatives in: | ||||||||||||||||||||||||||||||||||||||||||||
| Modco or funds withheld arrangements |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||
| Indexed annuity products |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||
| Total non-hedging derivatives |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||
| Derivatives designated as hedging instruments: | ||||||||||||||||||||||||||||||||||||||||||||
| Interest rate swaps | Foreign currency/Interest rate |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||
| Foreign currency swaps | Foreign currency |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||
| Foreign currency forwards | Foreign currency |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||
| Forward bond purchase commitments | Interest rate |
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||
| Total hedging derivatives |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||
| Total derivatives | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||||||
| Type of Fair Value Hedge | Hedged Item | Gains (Losses) Recognized for Derivatives | Gains (Losses) Recognized for Hedged Items | |||||||||||||||||
| Investment Related Gains (Losses), Net | ||||||||||||||||||||
| For the three months ended March 31, 2023: | ||||||||||||||||||||
| Foreign currency swaps | Foreign-denominated fixed maturity securities | $ |
(
|
$ |
|
|||||||||||||||
| For the three months ended March 31, 2022: | ||||||||||||||||||||
| Foreign currency swaps | Foreign-denominated fixed maturity securities | $ |
|
$ |
(
|
|||||||||||||||
| Three months ended March 31, | ||||||||||||||
| 2023 | 2022 | |||||||||||||
| Balance, beginning of period | $ |
(
|
$ |
(
|
||||||||||
| Gains (losses), net deferred in other comprehensive income (loss) |
|
(
|
||||||||||||
| Amounts reclassified to net investment income |
|
|
||||||||||||
| Amounts reclassified to interest expense |
(
|
|
||||||||||||
| Balance, end of period | $ |
(
|
$ |
(
|
||||||||||
| Derivative Type | Gains (Losses) Deferred in OCI | Gains (Losses) Reclassified into Income from AOCI | ||||||||||||||||||
| Net Investment Income | Interest Expense | |||||||||||||||||||
| For the three months ended March 31, 2023: | ||||||||||||||||||||
| Interest rate | $ |
|
$ |
|
$ |
|
||||||||||||||
| Foreign currency/interest rate |
(
|
(
|
|
|||||||||||||||||
| Total | $ |
|
$ |
(
|
$ |
|
||||||||||||||
| For the three months ended March 31, 2022: | ||||||||||||||||||||
| Interest rate | $ |
(
|
$ |
|
$ |
(
|
||||||||||||||
| Foreign currency/interest rate |
|
|
|
|||||||||||||||||
| Total | $ |
(
|
$ |
|
$ |
(
|
||||||||||||||
| Derivative Gains (Losses) Deferred in OCI | ||||||||||||||||||||||||||
| For the three months ended March 31, | ||||||||||||||||||||||||||
| Type of NIFO Hedge | 2023 | 2022 | ||||||||||||||||||||||||
| Foreign currency forwards | $ |
|
$ |
(
|
||||||||||||||||||||||
|
Gains (Losses) for the three months ended
March 31, |
||||||||||||||||||||
| Type of Non-hedging Derivative | Income Statement Location of Gains (Losses) | 2023 | 2022 | |||||||||||||||||
| Interest rate swaps | Investment related gains (losses), net | $ |
|
$ |
(
|
|||||||||||||||
| Interest rate options | Investment related gains (losses), net |
(
|
|
|||||||||||||||||
| Total return swaps | Investment related gains (losses), net |
|
|
|||||||||||||||||
| Interest rate futures | Investment related gains (losses), net |
|
|
|||||||||||||||||
| Equity futures | Investment related gains (losses), net |
(
|
|
|||||||||||||||||
| Foreign currency swaps | Investment related gains (losses), net |
|
|
|||||||||||||||||
| Foreign currency forwards | Investment related gains (losses), net |
(
|
(
|
|||||||||||||||||
| CPI swaps | Investment related gains (losses), net |
|
|
|||||||||||||||||
| Credit default swaps | Investment related gains (losses), net |
|
(
|
|||||||||||||||||
| Equity options | Investment related gains (losses), net |
(
|
|
|||||||||||||||||
| Subtotal |
(
|
(
|
||||||||||||||||||
| Embedded derivatives in: | ||||||||||||||||||||
| Modco or funds withheld arrangements | Investment related gains (losses), net |
|
(
|
|||||||||||||||||
| Indexed annuity products | Interest credited |
|
|
|||||||||||||||||
| Total non-hedging derivatives | $ |
|
$ |
(
|
||||||||||||||||
| March 31, 2023 | December 31, 2022 | |||||||||||||||||||||||||||||||||||||
|
Rating Agency Designation of Referenced Credit Obligations
(1)
|
Estimated Fair
Value of Credit Default Swaps |
Maximum
Amount of Future
Payments under
Credit Default
Swaps
(2)
|
Weighted
Average
Years to
Maturity
(3)
|
Estimated Fair
Value of Credit Default Swaps |
Maximum
Amount of Future
Payments under
Credit Default
Swaps
(2)
|
Weighted
Average
Years to
Maturity
(3)
|
||||||||||||||||||||||||||||||||
| AAA/AA+/AA/AA-/A+/A/A- | ||||||||||||||||||||||||||||||||||||||
| Single name credit default swaps | $ |
(
|
$ |
|
|
$ |
(
|
$ |
|
|
||||||||||||||||||||||||||||
| BBB+/BBB/BBB- | ||||||||||||||||||||||||||||||||||||||
| Single name credit default swaps |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Credit default swaps referencing indices |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| Subtotal |
|
|
|
|
|
|
||||||||||||||||||||||||||||||||
| BB+/BB/BB- | ||||||||||||||||||||||||||||||||||||||
| Single name credit default swaps |
(
|
|
|
(
|
|
|
||||||||||||||||||||||||||||||||
| Total | $ |
(
|
$ |
|
|
$ |
(
|
$ |
|
|
||||||||||||||||||||||||||||
|
Gross Amounts
Recognized |
Gross Amounts
Offset in the Balance Sheet |
Net Amounts
Presented in the Balance Sheet |
Financial
Instruments/Collateral
(1)
|
Net Amount | ||||||||||||||||||||||||||||
| March 31, 2023: | ||||||||||||||||||||||||||||||||
| Derivative assets | $ |
|
$ |
(
|
$ |
|
$ |
(
|
$ |
|
||||||||||||||||||||||
| Derivative liabilities |
|
(
|
|
(
|
|
|||||||||||||||||||||||||||
| December 31, 2022: | ||||||||||||||||||||||||||||||||
| Derivative assets |
|
(
|
|
(
|
|
|||||||||||||||||||||||||||
| Derivative liabilities |
|
(
|
|
(
|
|
|||||||||||||||||||||||||||
| March 31, 2023: | Fair Value Measurements Using: | |||||||||||||||||||||||||
| Total | Level 1 | Level 2 | Level 3 | |||||||||||||||||||||||
|
Assets:
(1)
|
||||||||||||||||||||||||||
| Fixed maturity securities available-for-sale: | ||||||||||||||||||||||||||
| Corporate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Canadian government |
|
|
|
|
||||||||||||||||||||||
| Japanese government |
|
|
|
|
||||||||||||||||||||||
| ABS |
|
|
|
|
||||||||||||||||||||||
| CMBS |
|
|
|
|
||||||||||||||||||||||
| RMBS |
|
|
|
|
||||||||||||||||||||||
| U.S. government |
|
|
|
|
||||||||||||||||||||||
| State and political subdivisions |
|
|
|
|
||||||||||||||||||||||
| Other foreign government |
|
|
|
|
||||||||||||||||||||||
| Total fixed maturity securities available-for-sale |
|
|
|
|
||||||||||||||||||||||
| Equity securities |
|
|
|
|
||||||||||||||||||||||
| Funds withheld at interest – embedded derivatives |
(
|
|
|
(
|
||||||||||||||||||||||
| Funds withheld at interest |
|
|
|
|
||||||||||||||||||||||
| Cash equivalents |
|
|
|
|
||||||||||||||||||||||
| Short-term investments |
|
|
|
|
||||||||||||||||||||||
| Other invested assets: | ||||||||||||||||||||||||||
| Derivatives |
|
|
|
|
||||||||||||||||||||||
| Other |
|
|
|
|
||||||||||||||||||||||
| Total other invested assets |
|
|
|
|
||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Liabilities: | ||||||||||||||||||||||||||
| Interest-sensitive contract liabilities – embedded derivatives | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Other liabilities: | ||||||||||||||||||||||||||
| Funds withheld at interest – embedded derivatives |
(
|
|
|
(
|
||||||||||||||||||||||
| Derivatives |
|
|
|
|
||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| December 31, 2022: | Fair Value Measurements Using: | |||||||||||||||||||||||||
| Total | Level 1 | Level 2 | Level 3 | |||||||||||||||||||||||
|
Assets:
(1)
|
||||||||||||||||||||||||||
| Fixed maturity securities available-for-sale: | ||||||||||||||||||||||||||
| Corporate | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Canadian government |
|
|
|
|
||||||||||||||||||||||
| Japanese government |
|
|
|
|
||||||||||||||||||||||
| ABS |
|
|
|
|
||||||||||||||||||||||
| CMBS |
|
|
|
|
||||||||||||||||||||||
| RMBS |
|
|
|
|
||||||||||||||||||||||
| U.S. government |
|
|
|
|
||||||||||||||||||||||
| State and political subdivisions |
|
|
|
|
||||||||||||||||||||||
| Other foreign government |
|
|
|
|
||||||||||||||||||||||
| Total fixed maturity securities available-for-sale |
|
|
|
|
||||||||||||||||||||||
| Equity securities |
|
|
|
|
||||||||||||||||||||||
| Funds withheld at interest – embedded derivatives |
(
|
|
|
(
|
||||||||||||||||||||||
| Funds withheld at interest |
|
|
|
|
||||||||||||||||||||||
| Cash equivalents |
|
|
|
|
||||||||||||||||||||||
| Short-term investments |
|
|
|
|
||||||||||||||||||||||
| Other invested assets: | ||||||||||||||||||||||||||
| Derivatives |
|
|
|
|
||||||||||||||||||||||
| Other |
|
|
|
|
||||||||||||||||||||||
| Total other invested assets |
|
|
|
|
||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Liabilities: | ||||||||||||||||||||||||||
| Interest-sensitive contract liabilities – embedded derivatives | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Other liabilities: | ||||||||||||||||||||||||||
| Funds withheld at interest – embedded derivatives |
(
|
|
|
(
|
||||||||||||||||||||||
| Derivatives |
|
|
|
|
||||||||||||||||||||||
| Total | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Estimated Fair Value | Valuation Technique | Unobservable Inputs | Range (Weighted Average) | ||||||||||||||||||||||||||||||||||||||
| March 31, 2023 | December 31, 2022 | March 31, 2023 | December 31, 2022 | ||||||||||||||||||||||||||||||||||||||
| Assets: | |||||||||||||||||||||||||||||||||||||||||
| Corporate | $ |
|
$ |
|
Market comparable securities | Liquidity premium |
|
|
|||||||||||||||||||||||||||||||||
| EBITDA Multiple |
|
|
|||||||||||||||||||||||||||||||||||||||
| ABS |
|
|
Market comparable securities | Liquidity premium |
|
|
|||||||||||||||||||||||||||||||||||
| U.S. government |
|
|
Market comparable securities | Liquidity premium |
|
|
|||||||||||||||||||||||||||||||||||
| Equity securities |
|
|
Market comparable securities | EBITDA Multiple |
|
|
|||||||||||||||||||||||||||||||||||
| Funds withheld at interest – embedded derivatives |
|
(
|
Total return swap | Mortality |
|
|
|||||||||||||||||||||||||||||||||||
| Lapse |
|
|
|||||||||||||||||||||||||||||||||||||||
| Withdrawal |
|
|
|||||||||||||||||||||||||||||||||||||||
| CVA |
|
|
|||||||||||||||||||||||||||||||||||||||
| Crediting rate |
|
|
|||||||||||||||||||||||||||||||||||||||
| Liabilities: | |||||||||||||||||||||||||||||||||||||||||
| Interest-sensitive contract liabilities – embedded derivatives – indexed annuities |
|
|
Discounted cash flow | Mortality |
|
|
|||||||||||||||||||||||||||||||||||
| Lapse |
|
|
|||||||||||||||||||||||||||||||||||||||
| Withdrawal |
|
|
|||||||||||||||||||||||||||||||||||||||
| Option budget projection |
|
|
|||||||||||||||||||||||||||||||||||||||
|
For the three months ended March 31, 2023:
|
Fixed maturity securities available-for-sale |
Funds
withheld at interest –embedded derivatives, net
(1)
|
Funds
withheld at interest |
Interest-sensitive contract
liabilities – embedded derivatives |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Corporate | Foreign govt | Structured securities | U.S. and local govt | Equity securities | Cash equivalents | Short-term investments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair value, beginning of period | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
$ |
(
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Total gains/losses (realized/unrealized) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Included in earnings, net: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net investment income |
|
|
|
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investment related gains (losses), net |
(
|
|
|
|
|
|
(
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Interest credited |
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Included in other comprehensive income (loss) |
|
|
|
(
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Purchases
(2)
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Sales
(2)
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Settlements
(2)
|
(
|
|
(
|
(
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Transfers into Level 3 |
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Transfers out of Level 3 |
|
|
(
|
(
|
|
|
(
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair value, end of period | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Included in earnings, net: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net investment income | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Investment related gains (losses), net |
(
|
|
|
|
|
|
(
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Interest credited |
|
|
|
|
|
|
|
|
|
(
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Included in other comprehensive income (loss) |
|
|
|
(
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
For the three months ended March 31, 2022:
|
Fixed maturity securities available-for-sale |
Funds
withheld at interest –embedded derivatives, net
(1)
|
Funds
withheld at interest |
Interest-sensitive contract
liabilities – embedded derivatives |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Corporate | Foreign govt | Structured securities | U.S. and local govt | Equity securities | Cash equivalents | Short-term investments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair value, beginning of period | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Total gains/losses (realized/unrealized) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Included in earnings, net: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net investment income |
|
|
|
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investment related gains (losses), net |
|
|
(
|
|
(
|
|
|
(
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Interest credited |
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Included in other comprehensive income (loss) |
(
|
(
|
(
|
(
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Purchases
(2)
|
|
|
|
|
|
|
|
|
|
(
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Sales
(2)
|
(
|
|
(
|
|
(
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Settlements
(2)
|
(
|
|
(
|
(
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Transfers into Level 3 |
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Transfers out of Level 3 |
(
|
|
|
(
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair value, end of period | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Total gains/losses (realized/unrealized) recorded for the period relating to those Level 3 assets and liabilities that were still held at the end of the period | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Included in earnings, net: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net investment income | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
|
$ |
(
|
$ |
|
||||||||||||||||||||||||||||||||||||||||||||||||
| Investment related gains (losses), net |
|
|
(
|
|
(
|
|
|
(
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Claims and other policy benefits |
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Interest credited |
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Included in other comprehensive income (loss) |
(
|
(
|
(
|
(
|
|
|
|
|
(
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| March 31, 2023: |
Carrying Value
(1)
|
Estimated
Fair Value |
Fair Value Measurement Using: | |||||||||||||||||||||||||||||||||||
| Level 1 | Level 2 | Level 3 | ||||||||||||||||||||||||||||||||||||
| Assets: | ||||||||||||||||||||||||||||||||||||||
| Mortgage loans | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||
| Policy loans |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Funds withheld at interest |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Limited partnerships – cost method |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Cash and cash equivalents |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Short-term investments |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Other invested assets |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Accrued investment income |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||||||||||||||||||||
| Interest-sensitive contract liabilities | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||
| Other liabilities – funds withheld at interest |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Long-term debt |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| December 31, 2022: | ||||||||||||||||||||||||||||||||||||||
| Assets: | ||||||||||||||||||||||||||||||||||||||
| Mortgage loans | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||
| Policy loans |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Funds withheld at interest |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Limited partnerships – cost method |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Cash and cash equivalents |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Short-term investments |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Other invested assets |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Accrued investment income |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||||||||||||||||||||
| Interest-sensitive contract liabilities | $ |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||||||||||
| Other liabilities – funds withheld at interest |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Long-term debt |
|
|
|
|
|
|||||||||||||||||||||||||||||||||
| Pension Benefits | Other Benefits | |||||||||||||||||||||||||
| Three months ended March 31, | Three months ended March 31, | |||||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||||||
| Service cost | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| Interest cost |
|
|
|
|
||||||||||||||||||||||
| Expected return on plan assets |
(
|
(
|
|
|
||||||||||||||||||||||
| Amortization of prior service cost (credit) |
|
|
|
|
||||||||||||||||||||||
| Amortization of prior actuarial losses |
|
|
|
|
||||||||||||||||||||||
| Net periodic benefit cost | $ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||
| March 31, 2023 | December 31, 2022 | ||||||||||
| Limited partnerships and real estate joint ventures | $ |
|
$ |
|
|||||||
| Mortgage loans |
|
|
|||||||||
| Bank loans and private placements |
|
|
|||||||||
| Lifetime mortgages |
|
|
|||||||||
| Commitment Period | Maximum Potential Obligation | ||||
| 2034 | $ |
|
|||
| 2035 |
|
||||
| 2036 |
|
||||
| 2037 |
|
||||
| 2038 |
|
||||
| 2039 |
|
||||
| 2046 |
|
||||
| Three months ended March 31, | ||||||||||||||||||||||||||
| Revenues: | 2023 | 2022 | ||||||||||||||||||||||||
| U.S. and Latin America: | ||||||||||||||||||||||||||
| Traditional | $ |
|
$ |
|
||||||||||||||||||||||
| Financial Solutions |
|
|
||||||||||||||||||||||||
| Total |
|
|
||||||||||||||||||||||||
| Canada: | ||||||||||||||||||||||||||
| Traditional |
|
|
||||||||||||||||||||||||
| Financial Solutions |
|
|
||||||||||||||||||||||||
| Total |
|
|
||||||||||||||||||||||||
| Europe, Middle East and Africa: | ||||||||||||||||||||||||||
| Traditional |
|
|
||||||||||||||||||||||||
| Financial Solutions |
|
|
||||||||||||||||||||||||
| Total |
|
|
||||||||||||||||||||||||
| Asia Pacific: | ||||||||||||||||||||||||||
| Traditional |
|
|
||||||||||||||||||||||||
| Financial Solutions |
|
|
||||||||||||||||||||||||
| Total |
|
|
||||||||||||||||||||||||
| Corporate and Other |
|
|
||||||||||||||||||||||||
| Total | $ |
|
$ |
|
||||||||||||||||||||||
| Three months ended March 31, | ||||||||||||||||||||||||||
| Income (loss) before income taxes: | 2023 | 2022 | ||||||||||||||||||||||||
| U.S. and Latin America: | ||||||||||||||||||||||||||
| Traditional | $ |
|
$ |
|
||||||||||||||||||||||
| Financial Solutions |
|
|
||||||||||||||||||||||||
| Total |
|
|
||||||||||||||||||||||||
| Canada: | ||||||||||||||||||||||||||
| Traditional |
|
|
||||||||||||||||||||||||
| Financial Solutions |
|
|
||||||||||||||||||||||||
| Total |
|
|
||||||||||||||||||||||||
| Europe, Middle East and Africa: | ||||||||||||||||||||||||||
| Traditional |
|
|
||||||||||||||||||||||||
| Financial Solutions |
|
|
||||||||||||||||||||||||
| Total |
|
|
||||||||||||||||||||||||
| Asia Pacific: | ||||||||||||||||||||||||||
| Traditional |
|
|
||||||||||||||||||||||||
| Financial Solutions |
(
|
(
|
||||||||||||||||||||||||
| Total |
|
|
||||||||||||||||||||||||
| Corporate and Other |
(
|
(
|
||||||||||||||||||||||||
| Total | $ |
|
$ |
|
||||||||||||||||||||||
| Assets: | March 31, 2023 | December 31, 2022 | ||||||||||||
| U.S. and Latin America: | ||||||||||||||
| Traditional | $ |
|
$ |
|
||||||||||
| Financial Solutions |
|
|
||||||||||||
| Total |
|
|
||||||||||||
| Canada: | ||||||||||||||
| Traditional |
|
|
||||||||||||
| Financial Solutions |
|
|
||||||||||||
| Total |
|
|
||||||||||||
| Europe, Middle East and Africa: | ||||||||||||||
| Traditional |
|
|
||||||||||||
| Financial Solutions |
|
|
||||||||||||
| Total |
|
|
||||||||||||
| Asia Pacific: | ||||||||||||||
| Traditional |
|
|
||||||||||||
| Financial Solutions |
|
|
||||||||||||
| Total |
|
|
||||||||||||
| Corporate and Other |
|
|
||||||||||||
| Total | $ |
|
$ |
|
||||||||||
| For the three months ended March 31, | ||||||||||||||||||||||||||||||||
| (Dollars in millions, except per share data) | 2023 | 2022 | 2023 vs 2022 | |||||||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||||||||||
| Net premiums | $ | 3,385 | $ | 3,155 | $ | 230 | ||||||||||||||||||||||||||
| Net investment income | 856 | 810 | 46 | |||||||||||||||||||||||||||||
| Investment related gains (losses), net | (77) | (139) | 62 | |||||||||||||||||||||||||||||
| Other revenues | 87 | 91 | (4) | |||||||||||||||||||||||||||||
| Total revenues | 4,251 | 3,917 | 334 | |||||||||||||||||||||||||||||
| Benefits and expenses | ||||||||||||||||||||||||||||||||
| Claims and other policy benefits | 3,063 | 2,871 | 192 | |||||||||||||||||||||||||||||
| Future policy benefits remeasurement (gains) losses | (26) | 58 | (84) | |||||||||||||||||||||||||||||
| Market risk benefits remeasurement (gains) losses | 14 | (34) | 48 | |||||||||||||||||||||||||||||
| Interest credited | 215 | 141 | 74 | |||||||||||||||||||||||||||||
| Policy acquisition costs and other insurance expenses | 331 | 344 | (13) | |||||||||||||||||||||||||||||
| Other operating expenses | 250 | 227 | 23 | |||||||||||||||||||||||||||||
| Interest expense | 50 | 42 | 8 | |||||||||||||||||||||||||||||
| Collateral finance and securitization expense | 3 | 1 | 2 | |||||||||||||||||||||||||||||
| Total benefits and expenses | 3,900 | 3,650 | 250 | |||||||||||||||||||||||||||||
|
Income (loss) before income taxes
|
351 | 267 | 84 | |||||||||||||||||||||||||||||
| Provision for income taxes | 98 | 70 | 28 | |||||||||||||||||||||||||||||
| Net income (loss) | $ | 253 | $ | 197 | $ | 56 | ||||||||||||||||||||||||||
| Net income attributable to noncontrolling interest | 1 | — | 1 | |||||||||||||||||||||||||||||
| Net income (loss) available to RGA, Inc. shareholders | $ | 252 | $ | 197 | $ | 55 | ||||||||||||||||||||||||||
| Earnings per share | ||||||||||||||||||||||||||||||||
| Basic earnings per share | $ | 3.77 | $ | 2.93 | $ | 0.84 | ||||||||||||||||||||||||||
| Diluted earnings per share | $ | 3.72 | $ | 2.91 | $ | 0.81 | ||||||||||||||||||||||||||
| Three months ended March 31, | |||||||||||||||||||||||||||||
| 2023 | 2022 | 2023 vs. 2022 | |||||||||||||||||||||||||||
| Modco/Funds withheld: | |||||||||||||||||||||||||||||
| Change in fair value of funds withheld embedded derivatives | $ | 37 | $ | (33) | $ | 70 | |||||||||||||||||||||||
| EIAs: | |||||||||||||||||||||||||||||
| Embedded derivatives – interest credited | 7 | 17 | (10) | ||||||||||||||||||||||||||
| Market Risk Benefits: | |||||||||||||||||||||||||||||
| Market risk benefits remeasurement gains (losses) | (14) | 34 | (48) | ||||||||||||||||||||||||||
| Related freestanding derivatives | 2 | (35) | 37 | ||||||||||||||||||||||||||
| Net effect | (12) | (1) | (11) | ||||||||||||||||||||||||||
| Total net effect after freestanding derivatives | $ | 32 | $ | (17) | $ | 49 | |||||||||||||||||||||||
| For the three months ended March 31, | ||||||||||||||||||||
| (dollars in millions) | 2023 | 2022 | 2023 vs 2022 | |||||||||||||||||
| Revenues | ||||||||||||||||||||
| Net premiums | $ | 1,778 | $ | 1,556 | $ | 222 | ||||||||||||||
| Net investment income | 474 | 546 | (72) | |||||||||||||||||
| Investment related gains (losses), net | 19 | (78) | 97 | |||||||||||||||||
| Other revenues | 56 | 60 | (4) | |||||||||||||||||
| Total revenues | 2,327 | 2,084 | 243 | |||||||||||||||||
| Benefits and expenses | ||||||||||||||||||||
| Claims and other policy benefits | 1,646 | 1,516 | 130 | |||||||||||||||||
| Future policy benefits remeasurement (gains) losses | 3 | 83 | (80) | |||||||||||||||||
| Market risk benefits remeasurement (gains) losses | 14 | (34) | 48 | |||||||||||||||||
| Interest credited | 147 | 124 | 23 | |||||||||||||||||
| Policy acquisition costs and other insurance expenses | 223 | 223 | — | |||||||||||||||||
| Other operating expenses | 59 | 55 | 4 | |||||||||||||||||
| Total benefits and expenses | 2,092 | 1,967 | 125 | |||||||||||||||||
| Income (loss) before income taxes | $ | 235 | $ | 117 | $ | 118 | ||||||||||||||
| For the three months ended March 31, | ||||||||||||||||||||
| (dollars in millions) | 2023 | 2022 | 2023 vs 2022 | |||||||||||||||||
| Revenues | ||||||||||||||||||||
| Net premiums | $ | 1,615 | $ | 1,541 | $ | 74 | ||||||||||||||
| Net investment income | 193 | 289 | (96) | |||||||||||||||||
| Investment related gains (losses), net | (1) | 15 | (16) | |||||||||||||||||
| Other revenues | 5 | 6 | (1) | |||||||||||||||||
| Total revenues | 1,812 | 1,851 | (39) | |||||||||||||||||
| Benefits and expenses | ||||||||||||||||||||
| Claims and other policy benefits | 1,447 | 1,447 | — | |||||||||||||||||
| Future policy benefits remeasurement (gains) losses | 7 | 103 | (96) | |||||||||||||||||
| Market risk benefits remeasurement (gains) losses | — | — | — | |||||||||||||||||
| Interest credited | 18 | 17 | 1 | |||||||||||||||||
| Policy acquisition costs and other insurance expenses | 175 | 181 | (6) | |||||||||||||||||
| Other operating expenses | 44 | 43 | 1 | |||||||||||||||||
| Total benefits and expenses | 1,691 | 1,791 | (100) | |||||||||||||||||
| Income (loss) before income taxes | $ | 121 | $ | 60 | $ | 61 | ||||||||||||||
| Key metrics | ||||||||||||||||||||
| Life reinsurance in force | $1,676.8 billion | $1,645.1 billion | ||||||||||||||||||
| Future policy benefits remeasurement (gains) losses | ||||||||||||||||||||
| Effect of changes in cash flow assumptions | $ | — | $ | — | ||||||||||||||||
| Effect of actual variances from expected experience | $ | 7 | $ | 103 | ||||||||||||||||
|
Loss ratio
(1)
|
90.0 | % | 100.6 | % | ||||||||||||||||
| Policy acquisition costs and other insurance expenses as a percentage of net premiums | 10.8 | % | 11.7 | % | ||||||||||||||||
| Other operating expenses as a percentage of net premiums | 2.7 | % | 2.8 | % | ||||||||||||||||
| For the three months ended March 31, | 2023 | 2022 | 2023 vs 2022 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| (dollars in millions) | Asset-Intensive | Capital Solutions | Total | Asset-Intensive | Capital Solutions | Total | Asset-Intensive | Capital Solutions | Total | ||||||||||||||||||||||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net premiums | $ | 163 | $ | — | $ | 163 | $ | 15 | $ | — | $ | 15 | $ | 148 | $ | — | $ | 148 | |||||||||||||||||||||||||||||||||||
| Net investment income | 280 | 1 | 281 | 256 | 1 | 257 | 24 | — | 24 | ||||||||||||||||||||||||||||||||||||||||||||
| Investment related gains (losses), net | 20 | — | 20 | (93) | — | (93) | 113 | — | 113 | ||||||||||||||||||||||||||||||||||||||||||||
| Other revenues | 25 | 26 | 51 | 26 | 28 | 54 | (1) | (2) | (3) | ||||||||||||||||||||||||||||||||||||||||||||
| Total revenues | 488 | 27 | 515 | 204 | 29 | 233 | 284 | (2) | 282 | ||||||||||||||||||||||||||||||||||||||||||||
| Benefits and expenses | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Claims and other policy benefits | 199 | — | 199 | 69 | — | 69 | 130 | — | 130 | ||||||||||||||||||||||||||||||||||||||||||||
| Future policy benefits remeasurement (gains) losses | (4) | — | (4) | (20) | — | (20) | 16 | — | 16 | ||||||||||||||||||||||||||||||||||||||||||||
| Market risk benefits remeasurement (gains) losses | 14 | — | 14 | (34) | — | (34) | 48 | — | 48 | ||||||||||||||||||||||||||||||||||||||||||||
| Interest credited | 129 | — | 129 | 107 | — | 107 | 22 | — | 22 | ||||||||||||||||||||||||||||||||||||||||||||
| Policy acquisition costs and other insurance expenses | 46 | 2 | 48 | 41 | 1 | 42 | 5 | 1 | 6 | ||||||||||||||||||||||||||||||||||||||||||||
| Other operating expenses | 11 | 4 | 15 | 9 | 3 | 12 | 2 | 1 | 3 | ||||||||||||||||||||||||||||||||||||||||||||
| Total benefits and expenses | 395 | 6 | 401 | 172 | 4 | 176 | 223 | 2 | 225 | ||||||||||||||||||||||||||||||||||||||||||||
| Income before income taxes | $ | 93 | $ | 21 | $ | 114 | $ | 32 | $ | 25 | $ | 57 | $ | 61 | $ | (4) | $ | 57 | |||||||||||||||||||||||||||||||||||
| (dollars in millions) | Three months ended March 31, | |||||||||||||||||||||||||
| 2023 | 2022 | |||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||||
| Total revenues | $ | 488 | $ | 204 | ||||||||||||||||||||||
| Less: | ||||||||||||||||||||||||||
| Embedded derivatives – modco/funds withheld treaties | 38 | (48) | ||||||||||||||||||||||||
| Guaranteed minimum benefit riders and related free standing derivatives | 1 | (35) | ||||||||||||||||||||||||
| Revenues before certain derivatives and market risk benefits | 449 | 287 | ||||||||||||||||||||||||
| Benefits and expenses | ||||||||||||||||||||||||||
| Total benefits and expenses | 395 | 172 | ||||||||||||||||||||||||
| Less: | ||||||||||||||||||||||||||
| Equity-indexed annuities | (7) | (17) | ||||||||||||||||||||||||
| Market risk benefits remeasurement (gains) losses | 13 | (34) | ||||||||||||||||||||||||
| Benefits and expenses before certain derivatives and market risk benefits | 389 | 223 | ||||||||||||||||||||||||
| Income before income taxes: | ||||||||||||||||||||||||||
| Income (loss) before income taxes | 93 | 32 | ||||||||||||||||||||||||
| Less: | ||||||||||||||||||||||||||
| Embedded derivatives – modco/funds withheld treaties | 38 | (48) | ||||||||||||||||||||||||
| Market risk benefits remeasurement (gains) losses and related free standing derivatives | (12) | (1) | ||||||||||||||||||||||||
| Equity-indexed annuities | 7 | 17 | ||||||||||||||||||||||||
| Income before income taxes and certain derivatives | $ | 60 | $ | 64 | ||||||||||||||||||||||
| For the three months ended March 31, | ||||||||||||||||||||
| (dollars in millions) | 2023 | 2022 | 2023 vs 2022 | |||||||||||||||||
| Revenues | ||||||||||||||||||||
| Net premiums | $ | 318 | $ | 327 | $ | (9) | ||||||||||||||
| Net investment income | 62 | 59 | 3 | |||||||||||||||||
| Investment related gains (losses), net | 2 | 1 | 1 | |||||||||||||||||
| Other revenues | 4 | 4 | — | |||||||||||||||||
| Total revenues | 386 | 391 | (5) | |||||||||||||||||
| Benefits and expenses | ||||||||||||||||||||
| Claims and other policy benefits | 291 | 308 | (17) | |||||||||||||||||
| Future policy benefits remeasurement (gains) losses | (2) | (4) | 2 | |||||||||||||||||
| Market risk benefits remeasurement (gains) losses | — | — | — | |||||||||||||||||
| Interest credited | — | — | — | |||||||||||||||||
| Policy acquisition costs and other insurance expenses | 46 | 53 | (7) | |||||||||||||||||
| Other operating expenses | 12 | 10 | 2 | |||||||||||||||||
| Total benefits and expenses | 347 | 367 | (20) | |||||||||||||||||
| Income (loss) before income taxes | $ | 39 | $ | 24 | $ | 15 | ||||||||||||||
| For the three months ended March 31, | ||||||||||||||||||||
| (dollars in millions) | 2023 | 2022 | 2023 vs 2022 | |||||||||||||||||
| Revenues | ||||||||||||||||||||
| Net premiums | $ | 295 | $ | 304 | $ | (9) | ||||||||||||||
| Net investment income | 61 | 58 | 3 | |||||||||||||||||
| Investment related gains (losses), net | 2 | 1 | 1 | |||||||||||||||||
| Other revenues | 1 | 2 | (1) | |||||||||||||||||
| Total revenues | 359 | 365 | (6) | |||||||||||||||||
| Benefits and expenses | ||||||||||||||||||||
| Claims and other policy benefits | 270 | 287 | (17) | |||||||||||||||||
| Future policy benefits remeasurement (gains) losses | 3 | 1 | 2 | |||||||||||||||||
| Market risk benefits remeasurement (gains) losses | — | — | — | |||||||||||||||||
| Interest credited | — | — | — | |||||||||||||||||
| Policy acquisition costs and other insurance expenses | 45 | 52 | (7) | |||||||||||||||||
| Other operating expenses | 12 | 10 | 2 | |||||||||||||||||
| Total benefits and expenses | 330 | 350 | (20) | |||||||||||||||||
| Income (loss) before income taxes | $ | 29 | $ | 15 | $ | 14 | ||||||||||||||
| Key metrics | ||||||||||||||||||||
| Life reinsurance in force | $469.5 billion | $484.5 billion | ||||||||||||||||||
| Future policy benefits remeasurement (gains) losses | ||||||||||||||||||||
| Effect of changes in cash flow assumptions | $ | — | $ | — | ||||||||||||||||
| Effect of actual variances from expected experience | $ | 3 | $ | 1 | ||||||||||||||||
|
Loss ratio
(1)
|
92.5 | % | 94.7 | % | ||||||||||||||||
| Policy acquisition costs and other insurance expenses as a percentage of net premiums | 15.3 | % | 17.1 | % | ||||||||||||||||
| Other operating expenses as a percentage of net premiums | 4.1 | % | 3.3 | % | ||||||||||||||||
| For the three months ended March 31, | ||||||||||||||||||||
| (dollars in millions) | 2023 | 2022 | 2023 vs 2022 | |||||||||||||||||
| Revenues | ||||||||||||||||||||
| Net premiums | $ | 23 | $ | 23 | $ | — | ||||||||||||||
| Net investment income | 1 | 1 | — | |||||||||||||||||
| Investment related gains (losses), net | — | — | — | |||||||||||||||||
| Other revenues | 3 | 2 | 1 | |||||||||||||||||
| Total revenues | 27 | 26 | 1 | |||||||||||||||||
| Benefits and expenses | ||||||||||||||||||||
| Claims and other policy benefits | 21 | 21 | — | |||||||||||||||||
| Future policy benefits remeasurement (gains) losses | (5) | (5) | — | |||||||||||||||||
| Market risk benefits remeasurement (gains) losses | — | — | — | |||||||||||||||||
| Interest credited | — | — | — | |||||||||||||||||
| Policy acquisition costs and other insurance expenses | 1 | 1 | — | |||||||||||||||||
| Other operating expenses | — | — | — | |||||||||||||||||
| Total benefits and expenses | 17 | 17 | — | |||||||||||||||||
| Income (loss) before income taxes | $ | 10 | $ | 9 | $ | 1 | ||||||||||||||
| Key metrics | ||||||||||||||||||||
| Future policy benefits remeasurement (gains) losses | ||||||||||||||||||||
| Effect of changes in cash flow assumptions | $ | — | $ | — | ||||||||||||||||
| Effect of actual variances from expected experience | $ | (5) | $ | (5) | ||||||||||||||||
| For the three months ended March 31, | ||||||||||||||||||||
| (dollars in millions) | 2023 | 2022 | 2023 vs 2022 | |||||||||||||||||
| Revenues | ||||||||||||||||||||
| Net premiums | $ | 563 | $ | 579 | $ | (16) | ||||||||||||||
| Net investment income | 69 | 55 | 14 | |||||||||||||||||
| Investment related gains (losses), net | (6) | 16 | (22) | |||||||||||||||||
| Other revenues | 3 | 6 | (3) | |||||||||||||||||
| Total revenues | 629 | 656 | (27) | |||||||||||||||||
| Benefits and expenses | ||||||||||||||||||||
| Claims and other policy benefits | 494 | 514 | (20) | |||||||||||||||||
| Future policy benefits remeasurement (gains) losses | (17) | (19) | 2 | |||||||||||||||||
| Market risk benefits remeasurement (gains) losses | — | — | — | |||||||||||||||||
| Interest credited | — | (9) | 9 | |||||||||||||||||
| Policy acquisition costs and other insurance expenses | 20 | 24 | (4) | |||||||||||||||||
| Other operating expenses | 46 | 45 | 1 | |||||||||||||||||
| Total benefits and expenses | 543 | 555 | (12) | |||||||||||||||||
| Income (loss) before income taxes | $ | 86 | $ | 101 | $ | (15) | ||||||||||||||
| For the three months ended March 31, | ||||||||||||||||||||
| (dollars in millions) | 2023 | 2022 | 2023 vs 2022 | |||||||||||||||||
| Revenues | ||||||||||||||||||||
| Net premiums | $ | 438 | $ | 451 | $ | (13) | ||||||||||||||
| Net investment income | 23 | 19 | 4 | |||||||||||||||||
| Investment related gains (losses), net | — | — | — | |||||||||||||||||
| Other revenues | (1) | 3 | (4) | |||||||||||||||||
| Total revenues | 460 | 473 | (13) | |||||||||||||||||
| Benefits and expenses | ||||||||||||||||||||
| Claims and other policy benefits | 390 | 396 | (6) | |||||||||||||||||
| Future policy benefits remeasurement (gains) losses | (8) | (11) | 3 | |||||||||||||||||
| Market risk benefits remeasurement (gains) losses | — | — | — | |||||||||||||||||
| Interest credited | — | — | — | |||||||||||||||||
| Policy acquisition costs and other insurance expenses | 18 | 22 | (4) | |||||||||||||||||
| Other operating expenses | 33 | 32 | 1 | |||||||||||||||||
| Total benefits and expenses | 433 | 439 | (6) | |||||||||||||||||
| Income (loss) before income taxes | $ | 27 | $ | 34 | $ | (7) | ||||||||||||||
| Key metrics | ||||||||||||||||||||
| Life reinsurance in force | $759.6 billion | $850.7 billion | ||||||||||||||||||
| Future policy benefits remeasurement (gains) losses | ||||||||||||||||||||
| Effect of changes in cash flow assumptions | $ | — | $ | — | ||||||||||||||||
| Effect of actual variances from expected experience | $ | (8) | $ | (11) | ||||||||||||||||
|
Loss ratio
(1)
|
87.2 | % | 85.4 | % | ||||||||||||||||
| Policy acquisition costs and other insurance expenses as a percentage of net premiums | 4.1 | % | 4.9 | % | ||||||||||||||||
| Other operating expenses as a percentage of net premiums | 7.5 | % | 7.1 | % | ||||||||||||||||
| For the three months ended March 31, | ||||||||||||||||||||
| (dollars in millions) | 2023 | 2022 | 2023 vs 2022 | |||||||||||||||||
| Revenues | ||||||||||||||||||||
| Net premiums | $ | 125 | $ | 128 | $ | (3) | ||||||||||||||
| Net investment income | 46 | 36 | 10 | |||||||||||||||||
| Investment related gains (losses), net | (6) | 16 | (22) | |||||||||||||||||
| Other revenues | 4 | 3 | 1 | |||||||||||||||||
| Total revenues | 169 | 183 | (14) | |||||||||||||||||
| Benefits and expenses | ||||||||||||||||||||
| Claims and other policy benefits | 104 | 118 | (14) | |||||||||||||||||
| Future policy benefits remeasurement (gains) losses | (9) | (8) | (1) | |||||||||||||||||
| Market risk benefits remeasurement (gains) losses | — | — | — | |||||||||||||||||
| Interest credited | — | (9) | 9 | |||||||||||||||||
| Policy acquisition costs and other insurance expenses | 2 | 2 | — | |||||||||||||||||
| Other operating expenses | 13 | 13 | — | |||||||||||||||||
| Total benefits and expenses | 110 | 116 | (6) | |||||||||||||||||
| Income (loss) before income taxes | $ | 59 | $ | 67 | $ | (8) | ||||||||||||||
| Key metrics | ||||||||||||||||||||
| Future policy benefits remeasurement (gains) losses | ||||||||||||||||||||
| Effect of changes in cash flow assumptions | $ | — | $ | — | ||||||||||||||||
| Effect of actual variances from expected experience | $ | (9) | $ | (8) | ||||||||||||||||
| For the three months ended March 31, | |||||||||||||||||
| (dollars in millions) | 2023 | 2022 | 2023 vs 2022 | ||||||||||||||
| Revenues | |||||||||||||||||
| Net premiums | $ | 726 | $ | 693 | $ | 33 | |||||||||||
| Net investment income | 169 | 91 | 78 | ||||||||||||||
| Investment related gains (losses), net | (48) | (81) | 33 | ||||||||||||||
| Other revenues | 13 | 20 | (7) | ||||||||||||||
| Total revenues | 860 | 723 | 137 | ||||||||||||||
| Benefits and expenses | |||||||||||||||||
| Claims and other policy benefits | 632 | 533 | 99 | ||||||||||||||
| Future policy benefits remeasurement (gains) losses | (10) | (2) | (8) | ||||||||||||||
| Market risk benefits remeasurement (gains) losses | — | — | — | ||||||||||||||
| Interest credited | 54 | 20 | 34 | ||||||||||||||
| Policy acquisition costs and other insurance expenses | 62 | 66 | (4) | ||||||||||||||
| Other operating expenses | 56 | 54 | 2 | ||||||||||||||
| Total benefits and expenses | 794 | 671 | 123 | ||||||||||||||
| Income (loss) before income taxes | $ | 66 | $ | 52 | $ | 14 | |||||||||||
| For the three months ended March 31, | ||||||||||||||||||||
| (dollars in millions) | 2023 | 2022 | 2023 vs 2022 | |||||||||||||||||
| Revenues | ||||||||||||||||||||
| Net premiums | $ | 662 | $ | 650 | $ | 12 | ||||||||||||||
| Net investment income | 61 | 47 | 14 | |||||||||||||||||
| Investment related gains (losses), net | 3 | — | 3 | |||||||||||||||||
| Other revenues | 3 | 6 | (3) | |||||||||||||||||
| Total revenues | 729 | 703 | 26 | |||||||||||||||||
| Benefits and expenses | ||||||||||||||||||||
| Claims and other policy benefits | 563 | 494 | 69 | |||||||||||||||||
| Future policy benefits remeasurement (gains) losses | (9) | (2) | (7) | |||||||||||||||||
| Market risk benefits remeasurement (gains) losses | — | — | — | |||||||||||||||||
| Interest credited | — | — | — | |||||||||||||||||
| Policy acquisition costs and other insurance expenses | 46 | 54 | (8) | |||||||||||||||||
| Other operating expenses | 50 | 49 | 1 | |||||||||||||||||
| Total benefits and expenses | 650 | 595 | 55 | |||||||||||||||||
| Income (loss) before income taxes | $ | 79 | $ | 108 | $ | (29) | ||||||||||||||
| Key metrics | ||||||||||||||||||||
| Life reinsurance in force | $508.2 billion | $508.4 billion | ||||||||||||||||||
| Future policy benefits remeasurement (gains) losses | ||||||||||||||||||||
| Effect of changes in cash flow assumptions | $ | — | $ | — | ||||||||||||||||
| Effect of actual variances from expected experience | $ | (9) | $ | (2) | ||||||||||||||||
|
Loss ratio
(1)
|
83.7 | % | 75.7 | % | ||||||||||||||||
| Policy acquisition costs and other insurance expenses as a percentage of net premiums | 6.9 | % | 8.3 | % | ||||||||||||||||
| Other operating expenses as a percentage of net premiums | 7.6 | % | 7.5 | % | ||||||||||||||||
| For the three months ended March 31, | ||||||||||||||||||||
| (dollars in millions) | 2023 | 2022 | 2023 vs 2022 | |||||||||||||||||
| Revenues | ||||||||||||||||||||
| Net premiums | $ | 64 | $ | 43 | $ | 21 | ||||||||||||||
| Net investment income | 108 | 44 | 64 | |||||||||||||||||
| Investment related gains (losses), net | (51) | (81) | 30 | |||||||||||||||||
| Other revenues | 10 | 14 | (4) | |||||||||||||||||
| Total revenues | 131 | 20 | 111 | |||||||||||||||||
| Benefits and expenses | ||||||||||||||||||||
| Claims and other policy benefits | 69 | 39 | 30 | |||||||||||||||||
| Future policy benefits remeasurement (gains) losses | (1) | — | (1) | |||||||||||||||||
| Market risk benefits remeasurement (gains) losses | — | — | — | |||||||||||||||||
| Interest credited | 54 | 20 | 34 | |||||||||||||||||
| Policy acquisition costs and other insurance expenses | 16 | 12 | 4 | |||||||||||||||||
| Other operating expenses | 6 | 5 | 1 | |||||||||||||||||
| Total benefits and expenses | 144 | 76 | 68 | |||||||||||||||||
| Income (loss) before income taxes | $ | (13) | $ | (56) | $ | 43 | ||||||||||||||
| Key metrics | ||||||||||||||||||||
| Future policy benefits remeasurement (gains) losses | ||||||||||||||||||||
| Effect of changes in cash flow assumptions | $ | — | $ | — | ||||||||||||||||
| Effect of actual variances from expected experience | $ | (1) | $ | — | ||||||||||||||||
| For the three months ended March 31, | ||||||||||||||||||||||||||||||||
| (dollars in millions) | 2023 | 2022 | 2023 vs 2022 | |||||||||||||||||||||||||||||
| Revenues | ||||||||||||||||||||||||||||||||
| Net premiums | $ | — | $ | — | $ | — | ||||||||||||||||||||||||||
| Net investment income | 82 | 59 | 23 | |||||||||||||||||||||||||||||
| Investment related gains (losses), net | (44) | 3 | (47) | |||||||||||||||||||||||||||||
| Other revenues | 11 | 1 | 10 | |||||||||||||||||||||||||||||
| Total revenues | 49 | 63 | (14) | |||||||||||||||||||||||||||||
| Benefits and expenses | ||||||||||||||||||||||||||||||||
| Claims and other policy benefits | — | — | — | |||||||||||||||||||||||||||||
| Future policy benefits remeasurement (gains) losses | — | — | — | |||||||||||||||||||||||||||||
| Market risk benefits remeasurement (gains) losses | — | — | — | |||||||||||||||||||||||||||||
| Interest credited | 14 | 6 | 8 | |||||||||||||||||||||||||||||
| Policy acquisition costs and other insurance expenses | (20) | (22) | 2 | |||||||||||||||||||||||||||||
| Other operating expenses | 77 | 63 | 14 | |||||||||||||||||||||||||||||
| Interest expense | 50 | 42 | 8 | |||||||||||||||||||||||||||||
| Collateral finance and securitization expense | 3 | 1 | 2 | |||||||||||||||||||||||||||||
| Total benefits and expenses | 124 | 90 | 34 | |||||||||||||||||||||||||||||
| Loss before income taxes | $ | (75) | $ | (27) | $ | (48) | ||||||||||||||||||||||||||
| Three months ended March 31, | ||||||||||||||||||||||||||
| 2023 | 2022 | |||||||||||||||||||||||||
| Interest expense | $ | 49 | $ | 41 | ||||||||||||||||||||||
| Capital contributions to subsidiaries | 8 | 7 | ||||||||||||||||||||||||
| Dividends to shareholders | 53 | 49 | ||||||||||||||||||||||||
| Purchase of common stock | 50 | 25 | ||||||||||||||||||||||||
| Interest and dividend income | 37 | 108 | ||||||||||||||||||||||||
| March 31, 2023 | December 31, 2022 | |||||||||||||||||||||||||
| Cash and invested assets | $ | 762 | $ | 903 | ||||||||||||||||||||||
| Three months ended March 31, | |||||||||||
| 2023 | 2022 | ||||||||||
| Dividends to shareholders | $ | 53 | $ | 49 | |||||||
|
Purchase of common stock
(1)
|
50 | 25 | |||||||||
| Total amount paid to shareholders | $ | 103 | $ | 74 | |||||||
|
Number of common shares purchased
(1)
|
371,343 | 219,116 | |||||||||
| Average price per share | $ | 134.64 | $ | 114.09 | |||||||
| For the three months ended March 31, | ||||||||||||||
| 2023 | 2022 | |||||||||||||
| Sources: | ||||||||||||||
| Net cash provided by operating activities | $ | 1,574 | $ | 163 | ||||||||||
| Proceeds from long-term debt issuance | 500 | — | ||||||||||||
| Change in cash collateral for derivative positions and other arrangements | 17 | — | ||||||||||||
| Change in deposit asset on reinsurance | 11 | — | ||||||||||||
| Net deposits to investment-type policies and contracts | 96 | 1,864 | ||||||||||||
| Net change in noncontrolling interest | — | 90 | ||||||||||||
| Effect of exchange rate changes on cash | 1 | — | ||||||||||||
| Total sources | 2,199 | 2,117 | ||||||||||||
| Uses: | ||||||||||||||
| Net cash used in investing activities | 1,705 | 2,235 | ||||||||||||
| Dividends to stockholders | 53 | 49 | ||||||||||||
| Repayment of collateral finance and securitization notes | — | 14 | ||||||||||||
| Debt issuance costs | 6 | — | ||||||||||||
| Principal payments of long-term debt | 1 | 1 | ||||||||||||
| Purchases of treasury stock | 67 | 27 | ||||||||||||
| Change in cash collateral for derivative positions and other arrangements | — | 6 | ||||||||||||
| Change in deposit asset on reinsurance | — | 3 | ||||||||||||
| Effect of exchange rate changes on cash | — | 21 | ||||||||||||
| Total uses | 1,832 | 2,356 | ||||||||||||
| Net change in cash and cash equivalents | $ | 367 | $ | (239) | ||||||||||
| March 31, 2023 | % of Total | December 31, 2022 | % of Total | |||||||||||||||||||||||
| Fixed maturity securities available-for-sale | $ | 56,085 | 72.6 | % | $ | 52,901 | 72.0 | % | ||||||||||||||||||
| Equity securities | 138 | 0.2 | 134 | 0.2 | ||||||||||||||||||||||
| Mortgage loans | 6,833 | 8.8 | 6,590 | 9.0 | ||||||||||||||||||||||
| Policy loans | 1,221 | 1.6 | 1,231 | 1.7 | ||||||||||||||||||||||
| Funds withheld at interest | 5,976 | 7.7 | 6,003 | 8.2 | ||||||||||||||||||||||
| Limited partnerships and real estate joint ventures | 2,405 | 3.1 | 2,327 | 3.2 | ||||||||||||||||||||||
| Short-term investments | 246 | 0.3 | 154 | 0.2 | ||||||||||||||||||||||
| Other invested assets | 1,111 | 1.4 | 1,140 | 1.5 | ||||||||||||||||||||||
| Cash and cash equivalents | 3,294 | 4.3 | 2,927 | 4.0 | ||||||||||||||||||||||
| Total cash and invested assets | $ | 77,309 | 100.0 | % | $ | 73,407 | 100.0 | % | ||||||||||||||||||
| Three months ended March 31, | |||||||||||||||||
| 2023 | 2022 |
Increase/
(Decrease) |
|||||||||||||||
| Average invested assets at amortized cost | $ | 35,863 | $ | 35,271 | $ | 592 | |||||||||||
| Net investment income | $ | 415 | $ | 457 | $ | (42) | |||||||||||
| Annualized investment yield (ratio of net investment income to average invested assets at amortized cost) | 4.71 | % | 5.29 | % | (58) bps | ||||||||||||
| VII (included in net investment income) | $ | 39 | $ | 141 | $ | (102) | |||||||||||
| Annualized investment yield excluding VII (ratio of net investment income, excluding VII, to average invested assets, excluding assets with only VII, at amortized cost) | 4.45 | % | 3.80 | % | 65 bps | ||||||||||||
| March 31, 2023 | December 31, 2022 | |||||||||||||||||||||||||||||||||||||||||||
|
NAIC
Designation |
Rating Agency
Designation |
Amortized Cost |
Estimated
Fair Value |
% of Total | Amortized Cost |
Estimated
Fair Value |
% of Total | |||||||||||||||||||||||||||||||||||||
| 1 | AAA/AA/A | $ | 38,291 | $ | 35,308 | 63.0 | % | $ | 36,217 | $ | 32,295 | 61.1 | % | |||||||||||||||||||||||||||||||
| 2 | BBB | 19,832 | 17,658 | 31.5 | 20,188 | 17,580 | 33.2 | |||||||||||||||||||||||||||||||||||||
| 3 | BB | 2,811 | 2,698 | 4.8 | 2,734 | 2,607 | 5.0 | |||||||||||||||||||||||||||||||||||||
| 4 | B | 402 | 340 | 0.6 | 397 | 331 | 0.6 | |||||||||||||||||||||||||||||||||||||
| 5 | CCC and lower | 100 | 69 | 0.1 | 103 | 71 | 0.1 | |||||||||||||||||||||||||||||||||||||
| 6 | In or near default | 58 | 12 | — | 24 | 17 | — | |||||||||||||||||||||||||||||||||||||
| Total | $ | 61,494 | $ | 56,085 | 100.0 | % | $ | 59,663 | $ | 52,901 | 100.0 | % | ||||||||||||||||||||||||||||||||
| March 31, 2023 | December 31, 2022 | |||||||||||||||||||||||||||||||||||||
| Amortized Cost |
Estimated
Fair Value |
% of Total | Amortized Cost |
Estimated
Fair Value |
% of Total | |||||||||||||||||||||||||||||||||
| ABS: | ||||||||||||||||||||||||||||||||||||||
| Collateralized loan obligations (“CLOs”) | $ | 1,880 | $ | 1,775 | 26.1 | % | $ | 1,825 | $ | 1,702 | 26.4 | % | ||||||||||||||||||||||||||
| ABS, excluding CLOs | 2,590 | 2,328 | 34.2 | 2,499 | 2,176 | 33.8 | ||||||||||||||||||||||||||||||||
| Total ABS | 4,470 | 4,103 | 60.3 | 4,324 | 3,878 | 60.2 | ||||||||||||||||||||||||||||||||
| CMBS | 1,882 | 1,670 | 24.6 | 1,835 | 1,623 | 25.2 | ||||||||||||||||||||||||||||||||
| RMBS: | ||||||||||||||||||||||||||||||||||||||
| Agency | 473 | 432 | 6.4 | 476 | 427 | 6.6 | ||||||||||||||||||||||||||||||||
| Non-agency | 647 | 592 | 8.7 | 578 | 514 | 8.0 | ||||||||||||||||||||||||||||||||
| Total RMBS | 1,120 | 1,024 | 15.1 | 1,054 | 941 | 14.6 | ||||||||||||||||||||||||||||||||
| Total | $ | 7,472 | $ | 6,797 | 100.0 | % | $ | 7,213 | $ | 6,442 | 100.0 | % | ||||||||||||||||||||||||||
| March 31, 2023 | December 31, 2022 | |||||||||||||||||||||||||
|
Recorded
Investment |
% of Total |
Recorded
Investment |
% of Total | |||||||||||||||||||||||
| U.S. Region: | ||||||||||||||||||||||||||
| West | $ | 2,533 | 36.7 | % | $ | 2,420 | 36.4 | % | ||||||||||||||||||
| South | 2,316 | 33.6 | 2,215 | 33.3 | ||||||||||||||||||||||
| Midwest | 1,177 | 17.1 | 1,147 | 17.2 | ||||||||||||||||||||||
| Northeast | 470 | 6.8 | 474 | 7.1 | ||||||||||||||||||||||
| Subtotal - U.S. | 6,496 | 94.2 | 6,256 | 94.0 | ||||||||||||||||||||||
| Canada | 238 | 3.5 | 239 | 3.6 | ||||||||||||||||||||||
| United Kingdom | 161 | 2.3 | 158 | 2.4 | ||||||||||||||||||||||
| Total | $ | 6,895 | 100.0 | % | $ | 6,653 | 100.0 | % | ||||||||||||||||||
| Three months ended March 31, | |||||||||||||||||||||||
| 2023 | 2022 | ||||||||||||||||||||||
| Change in allowance for credit losses on fixed maturity securities | $ | (42) | $ | (11) | |||||||||||||||||||
| Impairments on fixed maturity securities | (1) | (1) | |||||||||||||||||||||
| Change in mortgage loan allowance for credit losses | 3 | (2) | |||||||||||||||||||||
| Total | $ | (40) | $ | (14) | |||||||||||||||||||
|
Total Number of Shares
Purchased
(1)
|
Average Price Paid per
Share |
Total Number of Shares
Purchased as Part of
Publicly Announced Plans
or Programs
(1)
|
Maximum Number (or
Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plan or Program |
|||||||||||||||||||||||
| January 1, 2023 – January 31, 2023 | 87,598 | $ | 140.84 | — | $ | 350,001,793 | ||||||||||||||||||||
| February 1, 2023 – February 28, 2023 | 31,272 | $ | 149.28 | — | $ | 350,001,793 | ||||||||||||||||||||
| March 1, 2023 – March 31, 2023 | 371,784 | $ | 134.63 | 371,343 | $ | 300,003,480 | ||||||||||||||||||||
|
Exhibit
Number |
Description | |||||||
| 101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | |||||||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibits 101). | |||||||
| Term or Acronym | Definition | |||||||
| RGA Reinsurance | RGA Reinsurance Company | |||||||
| Parkway Re | Parkway Reinsurance Company | |||||||
| Rockwood Re | Rockwood Reinsurance Company | |||||||
| Castlewood Re | Castlewood Reinsurance Company | |||||||
| Chesterfield Re | Chesterfield Reinsurance Company | |||||||
| Chesterfield Financial | Chesterfield Financial Holdings LLC | |||||||
| RGA Life and Annuity | RGA Life and Annuity Insurance Company | |||||||
| Timberlake Re | Timberlake Reinsurance Company II | |||||||
| Timberlake Financial | Timberlake Financial L.L.C. | |||||||
| RGA Canada | RGA Life Reinsurance Company of Canada | |||||||
| RGA Barbados | RGA Reinsurance Company (Barbados) Ltd. | |||||||
| RGA Americas | RGA Americas Reinsurance Company, Ltd. | |||||||
| Manor Re | Manor Reinsurance, Ltd. | |||||||
| RGA Atlantic | RGA Atlantic Reinsurance Company Ltd. | |||||||
| RGA Worldwide | RGA Worldwide Reinsurance Company, Ltd. | |||||||
| RGA Global | RGA Global Reinsurance Company, Ltd. | |||||||
| RGA Australia | RGA Reinsurance Company of Australia Limited | |||||||
| RGA International | RGA International Reinsurance Company dac | |||||||
| RGA South Africa | RGA Reinsurance Company of South Africa, Limited | |||||||
| Aurora National | Aurora National Life Assurance Company | |||||||
| Omnilife | Omnilife Insurance Company, Limited | |||||||
| Papara | Papara Financing LLC | |||||||
| Term or Acronym | Definition | |||||||
| A.M. Best | A.M. Best Company | |||||||
| ABS | Asset-backed securities | |||||||
| Actuary | A specialist in the mathematics of risk, especially as it relates to insurance calculations such as premiums, reserves, dividends, insurance rates and annuity rates. | |||||||
| Allowance | An amount paid by the reinsurer to the ceding company to help cover the ceding company's acquisition and other costs, especially commissions. Allowances are usually calculated as a large percentage (often 100%) of first-year premiums reinsured and smaller percentages of renewal premiums reinsured. | |||||||
| AOCI | Accumulated other comprehensive income (loss) | |||||||
| Asset-Intensive Reinsurance | A transaction (usually coinsurance or funds withheld and often involving reinsurance of annuities) where performance of the underlying assets, more so than any mortality risk, is a key element. | |||||||
| Assumed reinsurance | Insurance risk that a reinsurer accepts (assumes) from a ceding company. | |||||||
| ASU | Accounting Standards Update | |||||||
| ASU 2018-12 |
Accounting Standards Update
Financial Services – Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts
|
|||||||
| Automatic Reinsurance | Reinsurance arrangement whereby the ceding company and reinsurer agree that all business of a certain description will be ceded to the reinsurer. Under this arrangement, the ceding company performs underwriting decision-making within agreed-upon parameters for all business reinsured. | |||||||
| Bermuda Insurance Act | Bermuda's Insurance Act 1978 which distinguishes between insurers carrying on long-term business, insurers carrying on special purpose business and insurers carrying on general business. | |||||||
| BMA | Bermuda Monetary Authority | |||||||
| BSCR | Bermuda Solvency Capital Requirement | |||||||
| CCPA | California Consumer Privacy Act of 2018 | |||||||
| Capital-motivated reinsurance | Reinsurance, including financial reinsurance, whose primary purpose is to enhance the cedant's capital position. | |||||||
| Captive insurer | An insurance or reinsurance entity designed to provide insurance or reinsurance coverage for risks of the entity or entities by which it is owned or to which it is affiliated. | |||||||
| CECL | Accounting for current expected credit losses using the model based on expected losses rather than incurred losses. | |||||||
| Ceding company (also known as cedant) | An insurer that transfers, or cedes, risk to a reinsurer | |||||||
| CEO | RGA’s Chief Executive Officer | |||||||
| Cession | The insurance risk associated with a policy that is reinsured from an insurer to a reinsurer. | |||||||
| CFO | RGA’s Chief Financial Officer | |||||||
| CLOs | Collateralized loan obligations | |||||||
| CMBS | Commercial mortgage-backed securities, a part of our investment portfolio that consists of securities made up of commercial mortgages. Stated on our balance sheet at fair value. | |||||||
| Coinsurance (also known as original terms reinsurance) | A form of reinsurance under which the ceding company shares its premiums, death claims, surrender benefits, dividends and policy loans with the reinsurer, and the reinsurer pays expense allowances to reimburse the ceding company for a share of its expenses. | |||||||
| Coinsurance funds-withheld | A variant on coinsurance, in which the ceding company withholds assets equal to reserves and shares investment income on those assets with the reinsurer. | |||||||
| Counterparty | A party to a contract requiring or offering the exchange of risk. | |||||||
| Counterparty risk | The risk that a party to an agreement will be unable to fulfill its contractual obligations | |||||||
| CPI | Consumer price index | |||||||
| Critical illness (CI) insurance (also known as dread disease insurance) | Insurance that provides a guaranteed fixed sum upon diagnosis of a specified illness or condition such as cancer, heart disease, or permanent total disability. The coverage can be offered on a stand-alone basis or as an add-on to a life insurance policy. | |||||||
| CRO | RGA’s Chief Risk Officer | |||||||
| CVA | Credit valuation adjustment | |||||||
| DAC | Deferred policy acquisition costs: Costs of acquiring new business, which vary with and are directly related to the production of new business, have been deferred to the extent that such costs are deemed recoverable from future premiums or gross profits. | |||||||
| “Directors Plan” | Flexible Stock Plan for Directors | |||||||
| EBITDA | Earnings before interest, taxes, depreciation and amortization | |||||||
| EBS | Economic balance sheet framework as part of the Bermuda Solvency Capital Requirement that forms the basis for an insurer's enhanced capital requirements. | |||||||
| ECR | Enhanced capital requirement in accordance with the provisions of the Bermuda Insurance Act. | |||||||
| EEA | European Economic Area | |||||||
| EGP | Estimated gross profits. | |||||||
| EIAs | Equity-Indexed Annuities | |||||||
| EMEA | Europe, Middle East and Africa geographic segment | |||||||
| Enterprise Risk Management (ERM) | An enterprise-wide framework used by a firm to assess all risks facing the organization, manage mitigation strategies, monitor ongoing risks and report to interested audiences. | |||||||
| ESG | Environmental, social, and governance | |||||||
| ESTER | Euro Short-term Rate, an alternative to LIBOR being recommended by the European Central Bank | |||||||
| EU | European Union | |||||||
| Expected mortality | Number of deaths predicted to occur in a defined group of people. | |||||||
| FABN | Funding Agreement Backed Notes | |||||||
| Face amount | Amount payable at the death of the insured or at the maturity of the policy. | |||||||
| Facultative reinsurance | A type of reinsurance in which the reinsurer underwrites an individual risk submitted by the ceding company for a risk that is unusual, large, highly substandard or not covered by an automatic reinsurance treaty. Such risks are typically submitted to multiple reinsurers for competitive offers. | |||||||
| FASB | Financial Accounting Standards Board | |||||||
| FCA | Financial Conduct Authority | |||||||
| FHLB | Federal Home Loan Bank | |||||||
| FIA | Fixed indexed annuities | |||||||
| Financial reinsurance (also known as financially-motivated reinsurance) | A form of capital-motivated reinsurance that satisfies all regulatory requirements for risk transfer and is often designed to produce very predictable reinsurer profits as a percentage of the capital provided. | |||||||
| FSB | Financial Stability Board which consists of representatives of national financial authorities of the G20 nations. | |||||||
| FVO | Fair value option | |||||||
| GAAP | U.S. generally accepted accounting principles | |||||||
| GDPR | General Data Protection Regulation which establishes uniform data privacy laws across the European Union. | |||||||
| GICs | Guaranteed investment contracts | |||||||
| GILTI | Global intangible low-taxed income; a provision of U.S. Tax Reform that generally eliminates U.S. Federal income tax deferral on earnings of foreign subsidiaries. | |||||||
| GMAB | Guaranteed minimum accumulation benefits; a feature of some variable annuities that the Company reinsures | |||||||
| GMDB | Guaranteed minimum death benefits; a feature of some variable annuities that the Company reinsures | |||||||
| GMIB | Guaranteed minimum income benefits; a feature of some variable annuities that the Company reinsures | |||||||
| GMWB | Guaranteed minimum withdrawal benefits; a feature of some variable annuities that the Company reinsures | |||||||
| Group life insurance | Insurance policy under which the lives of a group of people, most commonly employees of a single company, are insured in accordance with the terms of one master contract. | |||||||
| Guaranteed issue life insurance | Insurance products that are guaranteed upon application, regardless of past health conditions. | |||||||
| IAIG | Internationally Active Insurance Group | |||||||
| IAIS | International Association of Insurance Supervisors | |||||||
| IBNR | Incurred but not reported; a liability on claims that are based on historical reporting patterns, but have not yet been reported. | |||||||
| IFRS (International Financial Reporting Standards) | Standards and interpretations adopted by the International Accounting Standards Board (IASB). | |||||||
| Individual life insurance | An insurance policy that insures the life of usually one and sometimes two or more related individuals, rather than a group of people. | |||||||
| In-force sum insured | A measure of insurance in effect at a specific date. | |||||||
| Initial public offering (IPO) | The first sale to the public of shares of common stock issued by a private company. IPOs often are issued by smaller companies seeking the capital to expand, but they also can be used by large mutual or privately owned companies seeking to become publicly traded. | |||||||
| LIBOR | London Interbank Offered Rate | |||||||
| Liquidity position | Combination of the company's cash, cash equivalents, and short-term investments | |||||||
| Longevity product | An insurance product that mitigates longevity risk by providing a stream of income for the duration of the policyholder's life. | |||||||
| Loss ratio | Claims and other policy benefits and Future policy benefits remeasurement (gains) losses as a percentage of net premiums | |||||||
| Market risk benefits | Contracts or contract features that provide protection to the policyholder from capital market risk and expose the Company to other-than-nominal capital market risk and are measured at fair value. | |||||||
| MDCI | Missouri Department of Commerce and Insurance | |||||||
| MMS | Minimum margin of solvency required to be maintained by the Company's Bermuda subsidiaries. | |||||||
| Modco | Modified coinsurance | |||||||
| Modified coinsurance | A variant on coinsurance in which the ceding company retains all the reserves, as well as assets backing reserves, and pays the reinsurer interest on the reinsurer's share of the reserves. | |||||||
| Moody’s | Moody’s Investors Service | |||||||
| Morbidity | A measure of the incidence of sickness or disease within a specific population group. | |||||||
| Mortality experience | Actual number of deaths occurring in a defined group of people. | |||||||
| Mortality risk reinsurance | Reinsurance that focuses primarily on transfer of mortality risk through coinsurance of term products or YRT. | |||||||
| NAIC | National Association of Insurance Commissioners | |||||||
| NAIC SAP | NAIC statutory accounting practices | |||||||
| NAV | Net asset value | |||||||
| NIFO | Net investments in foreign operations | |||||||
| NOL | Net operating loss | |||||||
| Non-traditional reinsurance | Usually synonymous with capital-motivated reinsurance, but includes any reinsurance of non-biometrical risks | |||||||
| Novation | The act of replacing one participating member of a contract with another, with all rights, duties and terms being transferred to the new party upon consent of all parties affected. | |||||||
| NYSE | New York Stock Exchange: the exchange where RGA is traded under the symbol “RGA” | |||||||
| OCI | Other comprehensive income (loss) | |||||||
| OTC | Derivatives that are privately negotiated contracts, which are known as over-the-counter derivatives | |||||||
| OTC Cleared | OTC derivatives that are cleared and settled through central clearing counterparties. | |||||||
| PBR | Principles-based reserves | |||||||
| PCAOB | Public Company Accounting Oversight Board (United States) | |||||||
| PCS | Performance Contingent Shares | |||||||
| Pension Plans | The Company's sponsored or administrated qualified and non-qualified defined benefit pension plans | |||||||
| Portfolio | The totality of risks assumed by an insurer or reinsurer. | |||||||
| Preferred risk coverage | Coverage designed for applicants who represent a better-than-average risk to an insurer. | |||||||
| Premium | Amount paid to insure a risk. | |||||||
| Primary insurance (also known as direct insurance) | Insurance business relating to contracts directly between insurers and policyholders. The insurance company is directly responsible to the policyholder. | |||||||
| Production | New business produced during a specified period. | |||||||
| PSU | Performance Share Units | |||||||
| Quota share (also known as 'first dollar' quota share) | A reinsurance arrangement in which the reinsurer receives a certain percentage of each risk reinsured. | |||||||
| RBC | Risk-Based Capital, which are guidelines promulgated by the NAIC and identify minimum capital requirements based upon business levels and asset mix. | |||||||
| Recapture | The right of the ceding company to cancel reinsurance under certain conditions. | |||||||
| Regulation XXX/Regulation A-XXX | U.S. Valuation of Life Policies Model Regulation implemented beginning in 2002 for various types of life insurance business, significantly increased the level of reserves that U.S. life insurance and life reinsurance companies must hold on their statutory financial statements for various types of life insurance business, primarily certain level premium term life products. | |||||||
| Reinsurance | The transfer of insurance risk from an insurer, referred to as the ceding company, to a reinsurer, in conjunction with the payment of a reinsurance premium. Through reinsurance, a reinsurer 'insures' an insurer. | |||||||
| Reserves | The amount required to be carried as a liability in the financial statement of an insurer or reinsurer to provide for future commitments under outstanding policies and contracts. | |||||||
| Retakaful | A form of reinsurance that is acceptable within Islamic law. See Takaful. | |||||||
| Retention limit | The maximum amount of risk a company will insure on one life. | |||||||
| Retrocession | A transfer of reinsurance risk from a reinsurer to another reinsurer, referred to as the retrocessionaire, in conjunction with the payment of a retrocession premium. Through retrocession, a retrocessionaire reinsures a reinsurer. | |||||||
| Retrocessionaire | A reinsurer that reinsures another reinsurer; see Retrocession. | |||||||
| RMBS | Residential mortgage-backed securities, a part of our investment portfolio that consists of securities made up of residential mortgages. Stated on our balance sheet at fair value. | |||||||
| RMSC | The Company's Risk Management Steering Committee | |||||||
| RSUs | Restricted Stock Units | |||||||
| S&P | Standard & Poor's | |||||||
| SARs | Stock Appreciation Rights | |||||||
| SEC | Securities and Exchange Commission | |||||||
| Securitization | The structuring of financial assets as collateral against which securities can be issued to investors. | |||||||
| Simplified issue life insurance | Insurance products with limited face amounts that require no or minimal underwriting. | |||||||
| SOFR | Secured Overnight Financing Rate, an alternative to LIBOR being proposed by the Federal Reserve Board | |||||||
| SPLRC | Special Purpose Life Reinsurance Captives | |||||||
| Statutory capital | The excess of statutory assets over statutory reserves, both of which are calculated in accordance with standards established by insurance regulators. | |||||||
| “Stock Plans” | The RGA flexible stock plan and the Flexible Stock Plan for Directors, collectively | |||||||
| Takaful | A form of insurance that is acceptable within Islamic law, and that is devised upon the principles of mutual advantage and group security. | |||||||
| TDR | Troubled Debt Restructuring | |||||||
| Tele-underwriting | A telephone interview process, during which an applicant's qualifications to be insured are assessed. | |||||||
| The “County” | The County of St. Louis, Missouri | |||||||
| The “Plan” | RGA Flexible Stock Plan | |||||||
| The Board | RGA's board of directors | |||||||
| The CARES Act | The Coronavirus Aid, Relief, and Economic Security Act | |||||||
| The Companies Act | The Bermuda's Companies Act of 1981 | |||||||
| The Company | Reinsurance Group of America, Incorporated and its subsidiaries, all of which are wholly owned, collectively | |||||||
| Treaty (also known as a contract) | A reinsurance agreement between a reinsurer and a ceding company. The three most common types of reinsurance treaties are YRT (yearly renewable term), coinsurance and modified coinsurance. The three most common methods of accepting reinsurance are automatic, facultative and facultative-obligatory. | |||||||
| TVaR | Tail Value-at-Risk used for calculated capital requirement for Bermuda subsidiaries. | |||||||
| U.S. Tax Reform | The U.S. Tax Cuts and Jobs Act of 2017 | |||||||
| UAE | United Arab Emirates | |||||||
| UK | United Kingdom | |||||||
| UL | Universal life insurance | |||||||
| Underwriting | The process that assesses the risk inherent in an application for insurance prior to acceptance of the policy. | |||||||
| Valuation | The periodic calculation of reserves, the funds that insurance companies are required to hold in order satisfy all future insurance obligations. | |||||||
| Variable life insurance | A form of whole life insurance under which the death benefit and the cash value of the policy fluctuate according to the performance of an investment fund. Most variable life insurance policies guarantee that the death benefit will not fall below a specified minimum. | |||||||
| VII | Variable investment income | |||||||
| VOCRA | Value of customer relationships acquired which represents the present value of the expected future profits associated with the expected future business acquired through existing customers of the acquired company or business. | |||||||
| VODA | Value of distribution agreements which represents the present value of future profits associated with the expected future business derived from distribution agreements. | |||||||
| Webcasts | Presentation of information broadcast over the Internet. | |||||||
| WorkWise | The Company's hybrid approach to flexible work arrangements. | |||||||
| Yearly Renewable Term (YRT) | A type of reinsurance which covers only mortality risk, with each year's premium based on the current amount of risk. | |||||||
|
Reinsurance Group of America, Incorporated
|
|||||||||||
| Date: May 5, 2023 | By: | /s/ Anna Manning | |||||||||
| Anna Manning | |||||||||||
| Chief Executive Officer | |||||||||||
|
(Principal Executive Officer)
|
|||||||||||
| Date: May 5, 2023 | By: | /s/ Todd C. Larson | |||||||||
| Todd C. Larson | |||||||||||
| Senior Executive Vice President and Chief Financial Officer | |||||||||||
| (Principal Financial and Accounting Officer) | |||||||||||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
Customers
| Customer name | Ticker |
|---|---|
| Globe Life Inc. | GL |
| Globe Life Inc. | GL |
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|